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1. INTRODUCTION 
Diabetic retinopathy is the major ocular 
complication of diabetes, both in terms of incidence 
and irreversible visual impairment. In spite of modern 
procedures for strict blood glucose control (DCCT, 
1993), laser treatment (ETDRS, 1991f; Aiello, 1994), 
vitrectomy (Gardner and Blankenship, 1994; Glaser, 
1994b), and classical pituitary ablation (Kohner et 
al., 1976; Speakman et al., 1966; Poulsen, 1953), it 
is a serious threat to normal vision. It is mainly a 
vascular disorder, primarily involving microvessels 
(Garner, 1970). Retinal capillaries undergo multiple, 
extremely complex structural alterations in response 
to the unavoidable hyperglycemia of long-term 
diabetes. Because many of the angiopathies occur on 
microscopic vessels before retinal changes can be 
detected clinically, differentiating primary from 
secondary events in the etiology of diabetic 
retinopathy has been difficult. Histopathological 
studies are critical for determining the earliest 
microscopic hanges that may cause the subsequent, 
clinically discernable, constellation of lesions 
comprising this disorder. Identification of the 
primary, triggering factors and the development of 
an appropriate animal model are necessary for the 
design and evaluation of therapies to prevent the 
many debilitating effects of this diabetic 
complication. 
A summary of the salient clinical and 
histopathological features of diabetic retinopathy is 
presented first (Sections 2-5) to provide a basis for 
subsequent discussions of experimental models 
(Sections 6 and 7), currently available therapeutics 
(Sections 8-10), possible underlying mechanisms 
(Sections 11 and 12) and the significance of the 
galactose-fed rat model (Section 13). There has been 
a deliberate attempt to keep Sections 2-5 free of any 
reference to animal data so that the true status of 
current information on the human condition can be 
evaluated as accurately and independently aspossible 
before assessing the relevancy of animal models. 
Emphasis throughout will be placed on the initial 
pathologies and their possible prevention or delay. 
There is evidence that the primary triggering event 
of diabetic retinopathy is the increase in tissue aldose 
reductase activity, which results from elevated 
circulating levels of glucose and other hexoses. The 
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reduction of excess glucose results in marked 
intracellular accumulation of sorbitol and unleashes a 
cascade of biochemical and structural anomalies. 
Clear causative relationships have been demonstrated 
between increased aldose reductase activity and the 
earliest structural changes of diabetic retinopathy: 
capillary basement membrane thickening and 
intramural pericyte loss. These, in turn, are probably 
causally linked to various subsequent retinal micro- 
angiopathies such as endothelial cell proliferation, 
microaneurysms, dilated channels and overt 
neovascularization. 
2. DIABETIC RETINOPATHY: INCIDENCE 
AND CLINICAL CHARACTERISTICS 
Diabetic retinopathy is the main cause of blindness 
by a single systemic disease in Great Britain (Garner, 
1970) and the leading cause of blindness in the 
United States in 20-74 yr-old individuals (Klein et 
aL, 1984a,b; Klein and Klein, 1985). The majority of 
individuals who have had diabetes mellitus for > 15 
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yr have developed some clinically visible signs of 
diabetic retinopathy: approximately 98% if they 
became diabetic before reaching 30 yr of age (Klein 
et al., 1984a) and 78% if they became diabetic after 
reaching 30 yr of age (Klein et al., 1984b). After 15 
yr of Type I diabetes, 50% of the subjects have 
proliferative retinopathy (Klein et al., 1984a). 
Blindness is 25-29 times more common in diabetic 
than in non-diabetic individuals (Fong and Rand, 
1994; Klein and Klein, 1985). It was estimated almost 
two decades ago (National Advisory Eye Council, 
1977) that 300,000 people in the United States were 
at risk of blindness from diabetic retinopathy. 
Because the prevalence of diabetes continues to 
increase (Warram et al., 1994), the number of people 
at risk is also increasing, perhaps now approaching 
500,000. Since insulin was introduced as a 
therapeutic agent for systemic diabetes mellitus 
(Banting and Best, 1922), many lives have been 
saved, but the incidence of diabetic complications 
has risen, especially for complications that usually 
take several years to develop, as does diabetic 
retinopathy (Klein and Klein, 1985; Krolewski et al., 
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1987; White, 1960). Whereas diabetes accounted for 
only 1.0% of new blindness in the United States in 
1930, it was responsible for 15% by 1960 (Winter, 
1960). 
Although some neurological changes occur 
(Bresnick et al., 1984), vascular pathology, primarily 
involving the retinal microvessels (capillaries) 
constitutes the main component of diabetic 
retinopathy (Cogan and Kuwabara, 1967a,b; Deruaz, 
1969; de Venecia et al., 1976; Garner, 1970). 
Blindness (defined as a best-corrected vision of 
20/200 or worse) results from one of the following, 
all of which are indicative of compromised vessels: 
(1) macular edema - -  when the increased 
permeability of damaged intraretinal vessels 
contributes to severe thickening at the center of the 
macula; (2) non-resolving vitreous hemorrhage - -  
when new, pre-retinal and intravitreal vessels rupture; 
(3) traction retinal detachment - -  when the 
fibrovascular proliferations and associated vitreous 
elements undergo sufficient contraction and/or 
displacement to detach the retina (Aiello, 1994; 
Davis, 1988; ETDRS, 1991d; Patz and Fine, 1977). 
The spectrum of retinal angiopathies that precedes 
these final conditions is very broad (Fig. 1; Sections 
5 and 11), involving not only a constellation of 
capillary lesions, which are probably primary, but 
changes in arterioles, venules and various rheological 
parameters of the retinal circulation (Ashton, 1983; 
Cogan et al., 1961; Cunha-Vaz, 1991; ETDRS, 
1991a,d,f; Garner, 1970, 1993). 
Most of the clinical signs and potential diagnostic 
characteristics of diabetic retinopathy were described 
in the 19th century, though not fully linked to diabetes 
(James, 1980). Ophthalmoscopically, no particular 
sequence of changes occurs consistently. 
Nevertheless, usually the first clinical manifestation 
of diabetic retinopathy is the appearance of one or 
more small, often clustered, microaneurysms u ually 
limited to the posterior pole. The posterior pole is 
defined as the central retina surrounding the optic 
disc and including, roughly, the area enclosed by the 
superior and inferior temporal vessels (Cogan, 1974). 
Moderate dilations of veins may accompany or 
precede microaneurysm detection (L'Esperance, 
1989). Frequently, small 'dot and blot' hemorrhages 
are intercalated between the microaneurysms and can 
be indistinguishable from them. Another relatively 
early change observed by central fundus examination 
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is the appearance of white to yellowish spots with 
rather distinct borders in the deep retinal layers. 
These so-called hard exudates consist of concentrated 
derivatives of plasma that escaped from the 
compromised vessels (Garner, 1994). They are found 
most frequently in association with macular edema, 
microaneurysms and other microangiopathies. A 
more advanced condition is marked by the formation 
of various intraretinal microvascular abnormalities, 
or IRMA (Section 5.6), which may be difficult to 
distinguish from intravitreal neovascularization. They 
represent irregular focal dilations and varicosities of 
capillaries, which have become large enough to be 
resolved ophthalmoscopically. IRMA are most 
clearly visible when they occur in the middle of the 
capillary plexus, where all other vessels (capillaries) 
are too small to be detected by fundus exam. Here 
they appear as isolated islands of enlarged, tortuous 
vascular segments ranging in size from barely visible 
to 30 txm or more in diameter. Cotton-wool spots 
(sometimes called soft exudates) occur only in the 
superficial layer of the retina. They are indicative of 
nerve damage resulting from ischemic conditions 
(Section 5.7). While their presence suggests 
advancing diabetic angiopathy, their severity is a 
relatively weak predictor of retinopathy progression 
(ETDRS, 1991d,f). They can occur at any time, even 
with relatively mild retinopathy (Brown et al., 1985; 
Kohner et al., 1969). Venous beading and macular 
edema are almost always associated with the severe 
non-proliferative stage. Although perivenous 
sheathing, perivenous exudates and arteriovenous 
nicking are minor lesions with respect to the 
frequency of their occurrence, they are included in 
the grading systems used in clinical trials (DRS, 
1981b). 
The proliferative stage of diabetic retinopathy is 
the most threatening with respect to the potential for 
causing severe loss of vision (ETDRS, 1991d,f). The 
new vessels usually arise on the surface of the optic 
disc or from veins near arteriovenous crossings 
(Michaelson, 1948; Taylor and Dobree, 1970). The 
areas of proliferation are often associated with regions 
of ischemia (Garner, 1994). The new vessels may 
grow directly into the vitreous or remain at least 
temporarily between the inner limiting membrane 
and the retina. Extraretinal neovascularization is 
usually followed soon by pre-retinal hemorrhages 
and fibrous proliferations, which form pre-retinal 
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membranes. Repeated hemorrhaging, retinal edema 
and/or retinal detachment may lead to irreversible 
visual loss. 
3. CLASSIFICATION AND GRADING OF 
MAIN FUNDUS CHANGES 
Classification systems of the clinically discernable 
retinal lesions are similar in complexity to the lesions 
themselves. Attempts to assign angiopathies tostages 
or use quantitative grading systems to assess the 
severity of diabetic retinopathy have undergone 
continual updating. Often, two broad categories have 
been utilized - -  background and proliferative 
diabetic retinopathy (Garner, 1994; L'Esperance, 
1989). Occasionally a pre-proliferative division has 
been added between the two (Benson et al., 1988; 
DRS, 1978; Sahel et al., 1994). However, many 
refinements have been developed as more precise 
information has become available and as 
modifications have been needed to meet the 
requirements ofparticular investigations (DRS, 1976, 
1978, 1981a,b; ETDRS, 1991c,d,f; Goldberg and 
Fine, 1969; L'Esperance, 1989). Now, essentially all 
grading systems utilize a set of standard fundus 
photographs to make precise and reproducible 
assessments (DRS, 1981a,b; ETDRS, 1991d,f). The 
lesions have been subdivided and grouped based on 
how predictive they are of the proliferative stage and 
ultimate blindness (Aiello, 1994; ETDRS, 1991d,f). 
As a result, each category contains eyes with similar 
prognoses, and there is an orderly progression of risk 
with increasing category (ETDRS, 19910. 
The findings that have emerged from the grading 
efforts tend to confirm early notions that the different 
retinal microangiopathies form a continuum: one 
stage ordinarily leading to another, after having arisen 
from a previous stage (L'Esperance, 1989). This 
assumption is generally accepted with the caveat hat 
some patients may never develop more than non- 
proliferative r tinopathy. The current systems (Aiello, 
1994; ETDRS, 1991a,d,f; L'Esperance, 1989) 
classify the lesions into mild, moderate, severe and 
very severe stages of non-proliferative diabetic 
retinopathy and mild, moderate and high-risk stages 
of proliferative diabetic retinopathy. Modified 
classification systems have been developed to utilize 
information gained from retinal fluorescein 
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angiography (ETDRS, 1991e,g). Although not 
utilized for diagnosis, a pre-retinopathy stage was 
proposed to accommodate evidence of some early 
retinal lesions, including vessel eakage, which are 
observed by vitreous fluorophotometry to occur 
before angiopathies are detectable by fundus 
photography or fluorescein angiography (Cunha-Vaz 
et al., 1975). 
There are marked changes in blood components 
and flow characteristics in diabetes (Feke et al., 
1994; Frank, 1994; Hatchell and Sinclair, 1994; 
Little, 1976), but none has yet been utilized in 
standardized classification systems (Aiello et al., 
1985; ETDRS, 1991b). 
4. ROLE OF TECHNOLOGICAL 
DEVELOPMENTS IN CORRELATING 
HISTOPATHOLOGIES 
Advancements in technological procedures have 
had a major impact on all aspects of investigation on 
the nature of d iabetes-related retinal 
microangiopathies. Microaneurysms were first 
described in 1877 by Nettleship in making a 
pathological report on a case for MacKenzie and 
were definitively associated with diabetes oon after 
(James, 1980). However, their rediscovery as an 
important entity in pathological material was delayed 
until the 1940s. By then, techniques of fundus 
photography (Bedell, 1939; James, 1980) and 
specialized procedures for vessel staining and 
injection with contrast media followed by 
examination of flat retinal whole mounts permitted 
histopathological correlations. These demonstrated 
that microaneurysms and minute, perfectly round 
hemorrhages are among the earliest changes of 
diabetic retinopathy (Ballantyne, 1945; Ballantyne 
and Loewenstein, 1944; Friedenwald, 1949, 1950; 
Ashton, 1949, 1950). 
The important role of pericytes in early 
microangiopathy (Kuwabara nd Cogan, 1963; Cogan 
and Kuwabara, 1967a) was not recognized until 
improved histopathological procedures (Kuwabara 
and Cogan, 1960) permitted enzyme digestion and 
removal of essentially all non-vascular tissues, 
leaving relatively intact vascular beds, which could 
be mounted and stained. Although various enzyme 
combinations were used including pepsin plus trypsin 
598 W. G. Robison et al. 
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and collagenase plus trypsin (Addison et  a l . ,  1970; 
Ashton, 1963; Ashton and Tripathi, 1975), use of the 
crude pancreatic trypsin extract originally reported 
(Kuwabara and Cogan, 1960) became standard in 
most ocular pathology laboratories for the next 30 yr. 
Recently, Laver et  al.  (1993) demonstrated that the 
most important component of the crude trypsin 
extract is elastase and that purified elastase alone in 
appropriate buffers provides cleaner preparations and 
more consistent results. The elastase digestion 
procedure permits the isolation of intact vascular 
beds from retinas previously resistant o processing 
owing to extraordinary vessel fragility. 
5. UNIQUENESS OF LESIONS TO DIABETIC 
RET INOPATHY 
Two histopathological lesions are essentially 
unique to diabetic retinopathy, and several others 
occur as a characteristic group of lesions, which 
itself forms a unique spectrum (Aiello, 1994; Benson 
et  a l . ,  1988; Cogan and Kuwabara, 1967b; Garner, 
1993). The two unique lesions - -  (1) a diffuse 
thickening of capillary basement membranes 
superimposed on age-related thickening; and (2) a 
selective loss of intramural pericytes - -  are not only 
unique in their occurrence, but they are the two 
earliest lesions to occur in diabetic retinopathy 
(Addison et  aL ,  1970; Ashton, 1974; Bloodworth, 
1967; Cogan and Kuwabara, 1967a; Kuwabara and 
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Cogan, 1963; Sahel et  a l . ,  1994; Speiser et  a l . ,  
1968; Yanoff, 1966). All subsequent lesions may 
occur in various other retinopathies, but even so, 
they usually are not expressed in the same way and 
are not accompanied by many of the other lesions of 
the typical 'diabetic retinopathy spectrum' (Table 1). 
Subsequent to capillary basement membrane 
thickening and selective pericyte loss, the most 
important histopathological lesions have been 
identified as the following: (1) endothelial 
proliferation; (2) capillary microaneurysms; and (3) 
capillary closure (Ashton, 1963). These correlate 
well with the five basic clinical pathological 
processes: (1) capillary occlusion; (2) permeability; 
(3) microaneurysms; (4) vessel-glial proliferation; 
and (5) glial-vitreal contraction (Aiello et  a l . ,  1985; 
Davis, 1988). Table 1 summarizes the salient 
histopathological nd clinical lesions that form the 
spectrum of retinal microangiopathies characteristic 
of diabetic retinopathy and indicates their occurrence 
and relative similarit ies in other retinal 
vasculopathies. It is clear that no other ocular or 
systemic disorder exhibits the same spectrum of 
retinal lesions in the same way as does diabetic 
retinopathy. No other disorder shows such a close 
association in the posterior pole among retinal areas 
of pericyte loss, non-perfusion,  punctate 
microaneurysms, 'dot and blot' hemorrhages, hard 
exudates, cotton-wool spots and IRMA (Cogan and 
Kuwabara, 1967b; Benson et  a l . ,  1988). Figure 1 
shows the probable sequences and inter-relationships 
Table 1 (continued) 
1. Ashton (1974); 2. Ashton (1983); 3. Bloodworth (1962); 4. Bloodworth (1963); 5. Bloodworth 
(1967); 6. Green et al. (1980); 7. Sugi (1966); 8. Section 5.1; Archer et al. (1991); 10. Ashton (1971); 11. 
Cogan and Kuwabara (1967a); 12. Garner (1970); 13. Speiser et al. (1968); 14. Yanoff (1966); 15. Archer 
(1976); 16. Ashton (1963); 17. Benson et al. (1988); 18. Cogan et al. (1961); 19. Kohner and Henkind 
(1970); 20. Palmer et aL (1994); 21. Weinberg and Seddon (1994); 22. Wise (1957); 23. Section 5.2; 24. 
Brown and Benson (1984); 25. Chaudhuri et al. (1981); 26. Hayreh (1970); 27. Garner (1994); 28. Keith 
et al. (1939); 29. Maguire and Schachat (1994); 30. Yanko et al. (1975); 31. Section 5.3; 32. Ashton 
(1950); 33. Ashton (1959); 34. Bresnick et al. (1976); 35. Bresnick (1994); 36. Brown et al. (1985); 37. 
Cogan and Kuwabara (1967b); 38. de Venetia et al. (1976); 39. Goldberg (1976); 40. Shimizu et al. 
(1981); 41. Toussaint (1968); 42. Section 5.4; 43. Section 11; 44. Ashton (1949); 45. Ballantyne (1945); 
46. Brown (1994a, 1994b); 47. Cogan (1974); 48. Duke et al. (1968); 49. Kuwabara et al. (1961); 50. 
Michaelson (1980); 51. Section 5.5; 52. Section 5.6; 53. Ashton and Harry (1963); 54. Kohner and Doilery 
(1969); 55. Kohner et al. (1969); 56. Mansour et al. (1990a); 57. Section 5.7; 58. Archer (1977); 59. Patz 
(1984); 60. Section 5.8; 61. Section 5.9. 
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of microangiopathies in the etiology of diabetic 
retinopathy. 
5.1. Capillary Basement Membrane Thickening 
and Selective Pericyte Loss 
A marked, diffuse thickening of the basement 
membranes which ensheathe capillaries is a hallmark 
of diabetic microangiopathy (Ashton, 1974, 1983; 
Williamson and Kilo, 1977). The basement 
membranes form a thin covering around the 
endothelial tube and completely envelop the 
intramural pericytes in capillaries of essentially all 
body tissues. A progressive, diffuse thickening also 
occurs with the normal aging process (Table 1), but 
it does not develop as rapidly or to the same extent 
as in diabetes. Whereas the basement membranes of 
retinal capillaries are normally approximately 80-120 
nm in thickness, they may become 3-5 times thicker 
in diabetic compared to non-diabetic subjects of 
comparable ages (Ashton, 1974, 1983; Bloodworth, 
1962, 1963, 1967; Toussaint and Dustin, 1963). The 
basement membrane thickening reported in other 
disorders is either focal rather than diffuse or only 
involves larger than capillary size vessels. Qualitative 
changes also occur in basement membrane 
components, but few analytical studies are available 
(Carlson, 1989; Carlson and Bjork, 1990; Toussaint 
and Dustin, 1963). 
There is no firm evidence for a selective loss of 
capillary pericytes in any condition other than 
diabetic retinopathy (Table 1). Normal aging may 
involve a selective loss of capillary endothelial cells 
(Kuwabara et al., 1961) or loss of both pericytes and 
endothelial cells, equally, but not a loss of pericytes 
alone. Sugi (1966) using data obtained from 170 
autopsy eyes of non-diabetic ndividuals with various 
other diseases or advanced age alone demonstrated 
significant loss of capillary cells, but no preferential 
loss of pericytes. Cogan and Kuwabara (1967a) 
clearly demonstrated degeneration of pericytes in 
retinal digests of autopsy eyes from diabetic patients 
by excellent micrographs of intramural pockets 
('ghosts') lacking stainable nuclei in capillaries with 
normally stained endothelial cell nuclei. They also 
reported that non-diabetic humans have 
approximately a 1:1 ratio of pericytes to endothelial 
cells whereas in diabetic persons the ratio decreases 
to 1:4, suggesting a selective loss of pericytes. These 
pioneer findings were confirmed and systematically 
documented in several subsequent s udies of trypsin 
digest preparations. Sugi (1966) documented a loss 
of capillary cells in eight out of nine diabetic retinas: 
of which, four exhibited loss of both endothelial cells 
and pericytes and another four had a greater loss of 
pericytes than endothelial cells. Yanoff (1966) 
reported retinal pericyte to endothelial cell ratios 
ranging from 1:1.0 to 1:1.2 in 11 autopsy eyes 
representing various diseases, including renal failure 
(uremia), compared to ratios of 1:1.5 to 1:18.3 in 11 
diabetic eyes. He found that the extent of decreased 
pericyte to endothelial cell ratio correlated irectly 
with numbers of microaneurysms. Speiser et al. 
(1968) analyzed 209 autopsy eyes: 46 of which were 
from diabetic persons, 126 from patients with various 
chronic disorders and 37 from individuals dying of 
non-disease-related causes. A statistically significant 
difference (p = 0.0001) was found in mean ratios of 
endothelial cells to pericytes in non-diabetic persons 
free of other diseases (1.1, range 0.52-1.56) 
compared to diabetic patients (5.2, range 0.62- 
17.54), indicating a selective loss of pericytes. The 
ratios for persons with other diseases ranged from 
1.3 to 1.8. These investigators also provided evidence 
that there was no increase in the number of 
endothelial cells per  capillary length, thus 
demonstrating that the change in ratio did indeed 
result from a selective loss of pericytes. 
In spite of a few reports to the contrary (de 
Oliveira, 1966), early supernormal thickening of 
capillary basement membrane and selective loss of 
intramural pericytes are considered hallmarks of 
diabetic microangiopathy and unique to diabetic 
retinopathy (Ashton, 1983; Bloodworth, 1967; Cogan 
and Kuwabara, 1967a; Deruaz, 1969; Speiser et al., 
1968; Sugi, 1966; Toussaint and Dustin, 1963; 
Williamson and Kilo, 1977; Yanoff, 1966). Even so, 
identification of the earliest ime when these lesions 
occur or which of the two lesions occurs first in 
human diabetic retinopathy has never been 
determined unequivocally. Both pericyte loss and 
capillary basement membrane thickening are 
microscopic changes that develop during the 
clinically silent phase. They do not match the criteria 
for the pre-retinopathy stage, which has been utilized 
by Cunha-Vaz (1991) for functional lesions. Whether 
they should be assigned to a new, 'microscopic 
stage' remains to be determined. 
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5.2. Dilations and Endothelial Cell Hypertrophy 
A moderate, uniform dilation of all the capillaries 
of the plexus occurs during the early stages of 
diabetic retinopathy (Cogan, 1974). Later, many 
varicosities and extraordinarily large dilations 
develop in localized regions, accompanied by 
endothelial cell hypertrophy. Many of the larger 
dilations form hyperceUular channels that traverse 
large acellular areas of the plexus. Others develop as 
'islands' isolated in the middle of capillary beds 
where they must depend on much smaller capillaries 
for perfusion (Kohner and Henkind, 1970; Section 
5.6). The cell proliferation involved has been 
considered to be an expression of intraretinal 
neovascularization involved in microaneurysm and 
IRMA formation (Kohner and Henkind, 1970; Wise, 
1957). Commonly in diabetes, but only rarely in 
other diseases (Table 1), capillaries that have 
undergone ndothelial cell hypertrophy, capillary 
dilation and varicose transformations are found side- 
by-side with non-perfused capillaries. 
5.3. Permeability and Hard Exudates 
The hard exudates, observed ophthalmoscopically 
as white to yellowish spots, indicate plasma leakage 
from compromised vessels. These exudates are 
aggregations of lipoprotein, cholesterol crystals and 
foamy histiocytes (Garner, 1994). Their 
topographical association with microaneurysms, 
capillary dilations and acellular capillaries in the 
posterior pole is characteristic of diabetic retinopathy 
(Table 1). Although the exudates of radiation 
retinopathy are very similar, they differ in that they 
are associated with disc edema. 
5.4. Capillary Non-perfusion, Occlusion and 
Acellularity 
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demonstrated by India ink injections of autopsy 
specimens (Ashton, 1950) and were later associated 
topographically with the areas of acellularity 
observed histopathologically (Cogan and Kuwabara, 
1967b; Kuwabara and Cogan, 1965) and with the 
areas of non-perfusion observed clinically (de 
Venecia et al., 1976; Kohner and Henkind, 1970; 
Bresnick et al., 1976). In diabetes, unlike most other 
disorders (Table 1), capillary non-perfusion is 
characteristically confined to the posterior pole and 
closely associated topographically with 
microaneurysms, dilated hypercellular capillaries, 
IRMA, hard exudates and cotton-wool spots (Ashton, 
1959; Cogan and Kuwabara, 1967b; Cogan et al., 
1961; Kohner and Henkind, 1970; Toussaint, 1968). 
5.5. Microaneurysms and 
Hemorrhages 
Intraretinal 
Small, 'dot and blot' intraretinal hemorrhages and 
microaneurysms are usually the first funduscopic 
signs of diabetic retinopathy (Ballantyne and 
Loewenstein, 1944; Davis, 1988; Michaelson, 1980; 
ETDRS, 1991d,f). Although they are barely 
distinguishable clinically, they are very distinct in 
structure when examined in histological sections. 
Many of the entities originally interpreted clinically 
to be small, well-defined hemorrhages ('dot and blot' 
type) were revealed to be microaneurysms by
histopathological exam (Ashton, 1949). Clinically, 
microaneurysms are the main hallmark of diabetic 
retinopathy (Table 1), although they do occur in 
other diseases and tissues (Garner, 1994). 
Examination of retinal digest preparations permits 
identification of occluded as well as patent 
microaneurysms. Summarizing their numerous 
histopathological studies of diabetic retinopathy 
Cogan and Kuwabara (1967b, p. 61) stated that 
"...microaneurysms aremuch more numerous than 
would have been suspected clinically." 
Capillary non-perfusion resulting from occlusion 
and associated with aceUularity isa prominent feature 
and is also considered a hallmark of diabetic 
retinopathy (Ashton, 1963; Benson et al., 1988; 
Bresnick, 1994; Bresnick et al., 1976; Garner, 1994). 
Retinal areas of capillary occlusion were first 
5.6. Irma, Shunts and Dilated Capillary 
Meshworks 
Intraretinal microvascular bnormalities (IRMA) 
originated as a clinical term although the 
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histopathological correlates had already been 
documented using various names for the individual 
components (Bloodworth, 1967; Cogan and 
Kuwabara, 1963; Cogan et al., 1961; Kohner and 
Henkind, 1970; Toussaint, 1968). IRMA were 
defined as: "...the abnormal vascular structures 
within the retina variously interpreted as 'shunt' 
vessels, dilated pre-existing capillaries, fusiform 
aneurysms, or intraretinal neovascularization" (Davis 
et al., 1969, p. 13). Transections of IRMA 
demonstrate a wide variety of changes that capillaries 
are capable of undergoing. The extent of capillary 
dilation, shape change and wall abnormality is truly 
extraordinary. The dilations can be greater than 10- 
fold and involve several capillary branches. The 
dilations can give rise to the formation of minute or 
large fusiform bulges, sausage-shaped varicosities, 
loops, complex coils, channels and networks, by 
various distortions of capillary walls (Cogan et al., 
1961; de Venecia et aL, 1976; Wise, 1957). IRMA 
are not limited to diabetic retinopathy, but tend to be 
most prominent in this disorder as it develops to the 
severe non-proliferative stage (Table 1). 
5.7. Cotton-Wool Spots and Ischemia 
Dollery, 1969; Kohner et al., 1969) or may not 
(Michaelson, 1980) be preceded by capillary dilations 
and occlusions. Though not permanent, cotton-wool 
spots persist for relatively long periods in diabetes, 
having half-lives of 8.1-17.2 months (Kohner et al., 
1969), compared to an average disappearance time of 
6.9 weeks in the acquired immunodeficiency 
syndrome (Mansour et al., 1990a). Their expressions 
in other disorders are noted in Table 1. 
5.8. Extraretinai Vessei-Glial Proliferation 
The neovascularization on the surface of the retina 
and/or optic disc is a hallmark of proliferative 
diabetic retinopathy (Davis, 1988). The new vessels 
arise from the venous circulation (Norton and 
Gutman, 1967) and are accompanied by development 
of fibrotic tissue, which becomes permanently 
connected to the strands of vitreal collagen and plays 
an important role in subsequent events. There is 
nothing completely specific about he process, but in 
other disorders it is not accompanied by the other 
lesions typical of diabetes and it is less likely to be 
limited to the posterior pole (Table 1). 
The cotton-wool spot (sometimes called soft 
exudate) is located in the nerve fiber cell layer. It is 
not an exudate at all: histologically, the cotton-wool 
spot is composed of an aggregate of several spherical 
to oblong bodies called cytoid bodies due to their 
resemblance to cells (Ashton and Harry, 1963; 
Garner, 1994; Wolter, 1959). By electron 
microscopy, each cytoid body was shown to contain 
accumulations of remnant debris from degenerated 
axoplasmic organelles including mitochondria, 
endoplasmic reticulum and nenrofilaments (Ashton, 
1970). The cytoid body probably results from 
obstruction of orthograde or retrograde axoplasmic 
transport (McLeod et al., 1977) and swelling with 
accumulation of cell organelles in a disrupted 
ganglion cell axon. Clinically, the cotton-wool spot 
is indicative of regions of non-perfusion and 
ischemia, often associated with arteriole occlusion 
(Destro and Gragoudas, 1994; Garner, 1994; Kohner 
and Dollery, 1969). Its development may be preceded 
by arteriolar occlusion, which may (Kohner and 
5.9. Extraretinal Hemorrhages, Glial-Vitreal 
Contraction and Macular Edema 
These three processes, any of which is capable of 
precipitating irreversible blindness in diabetic patients 
(Benson et al., 1988; Patz and Fine, 1977), differ 
little in their expression in other severe retinal 
vascular disorders. They are probably a general 
expression of a highly damaged and traumatized 
retina. 
6. EXPERIMENTAL MODELS OF DIABETIC 
RETINOPATHY 
The importance of animal models for studies of 
diabetic retinopathy cannot be overstated. Unless 
adequate amounts of tissue with detailed records are 
available, the correct timing and inter-relationships 
of etiological events as well as the causative factors 
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cannot be determined. Retinal biopsies from diabetic 
patients are not feasible. Presently, donor eyes from 
diabetic patients have become more available, but 
their usefulness i limited. The clinical histories are 
often incomplete and the variables introduced by 
postmortem autolytic processes are hard to minimize. 
Only appropriate animal models permit he collection 
and proper preservation of adequate amounts of tissue 
under experimentally-controlled conditions. 
Until recently, experimental studies on the basic 
mechanisms underlying the complete spectrum of 
angiopathies of diabetic retinopathy, and the testing 
of potential therapeutic agents have been severely 
hampered by the lack of reliable and convenient 
animal models (Engerman et al., 1982; Robison and 
Laver, 1993). Many animal models are available for 
diabetes as a systemic disease (Karasik and Hattori, 
1994; Shafrir, 1993), but the same cannot be said for 
diabetic retinopathy, which is not the disease itself, 
but one of its many complications. In fact, 
investigators who have evaluated many animal 
models of diabetes as a systemic disease have drawn 
attention to the striking lack of adequate models of 
diabetic retinopathy (Engerman et al., 1982; Patz 
and Maumenee, 1962). Some promising models are 
now emerging. These will be discussed here, whereas 
human disorders and animal systems that provide 
insight into certain elements of diabetic retinal 
angiopathies will be covered in Section 11. 
6.1. Diabetic Rodents 
Theoretically, strains of laboratory mice and rats 
should provide ideal sources for models of both 
systemic diabetes and its tissue complications, 
whether studying hereditary or induced iabetes. The 
genetic homogeneity, economy and handling 
conveniences are very favorable. There are, in fact, 
numerous mouse and rat models of systemic diabetes 
mellitus, and other rodent models are continually 
being defined (Cohen and Rosenmann, ~ 1990; Doi et 
al., 1990; Karasik and Hattori, 1994; Michaelis et 
al., 1988; Mori et aL, 1991; Shafrir, 1993), including 
the recently developed transgenic mouse models for 
studies of tissue-specific aspects of diabetes (Erickson 
et aL, 1990; Lee and Sarvetnick, 1993; Lutty et al., 
1994; Stewart et al., 1993). 
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However, the same is not true for diabetic 
complications. Neither the mouse nor the rat, whether 
its diabetes is hereditary or induced, has provided a 
completely satisfactory model for the entire set of 
diabetes-related retinal vascular complications of 
long-term hyperglycemia n man (Engerman et al., 
1982; Robison et al., 1991b). Several types of 
diabetic rats are good models for diabetic ataracts 
and diabetic keratopathy (Kinoshita and Nishimura, 
1988; Kinoshita et al., 1990; Robison and Laver, 
1993), but they usually only manifest some of the 
early lesions of diabetic retinopathy, such as capillary 
basement membrane thickening, intramural pericyte 
degeneration, endothelial cell proliferation and 
acellularity (Kern and Engerman, 1994; 
Papachristodoulou and Heath, 1977; Robison et al., 
1991b; Sima et al., 1983, 1985). They rarely exhibit 
microaneurysms (Agrawal et al., 1966; Boot- 
Handford and Heath, 1980; Cohen et al., 1972; 
Cohen and Rosenmann, 1990; Engerman et al., 1982; 
Papachristodoulou et al., 1976; Robison et al., 
1991b; Rosenmann et al., 1975; Yanko et al., 1971, 
1975). Except for rare reports such as that by 
Toussaint (1968), they have not been demonstrated 
to develop IRMA or proliferative retinopathy 
(Engerman et al., 1982; Kern and Engerman, 1994; 
Robison et al., 1991b; Cohen and Rosenmann, 1990). 
Significant thickening of retinal capillary 
basement membrane has been reported in 
streptozotocin-induced diabetic rats by several 
investigators: Fischer and Giirtner (1983) after 12 
months of hyperglycemia; Tilton et al. (1986) after 
6-9 months; McCaleb et al. (1991) after 6-8 months; 
and Kojima et al. (1985) by as early as 3 months. 
Pericyte ghosts have been documented in 
micrographs by several investigators in both retinal 
digests and electron micrographs (Chakrabarti et al., 
1987; Robison et al., 1991b). Pericyte ghosts, 
endothelial cell proliferation, capillary acellularity 
and varicose loops were documented in three different 
rat models with 6-8-month durations of diabetes 
(Robison et al., 1991b). Two were models for Type 
I diabetes: one by inheritance (BB Wistar diabetic); 
the other by streptozotocin jection (45 mg/kg). 
The third was a model for Type II diabetes 
(SHR/N-cp  diabetic rat). No microaneurysms, 
IRMA or more advanced lesions were found. 
Probably the relatively short life-spans of diabetic 
rats and/or their spontaneous reversion to euglyremia 
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(Kern and Engerman, 1994) preclude the 
development of lesions of the severe non-proliferative 
or proliferative stages of diabetic retinopathy. Such 
lesions are slow to develop, taking a minimum of 4 
yr and often taking more than 10 yr in humans 
(Krolewski et al., 1987). This would explain why 
only the early lesions, such as capillary basement 
membrane thickening and pericyte degeneration, 
occur consistently in diabetic rats. 
6.2. Diabetic Cats 
The domestic at has a retinal vascular pattern 
very similar to humans, but only a few reports of 
diabetic retinopathy in cats have appeared (Gepts 
and Toussaint, 1967; Toussaint, 1968; Mansour et 
al., 1990b). Gepts and Toussaint (1967) studied five 
spontaneously diabetic cats, some of which had 
documented urations as long as 7 months. They 
found that some had pericyte ghosts, focal 
acellularity, and/or varicose capillaries. Although 
many attempts to induce diabetes in cats have failed, 
diabetes can be achieved by procedures involving 
partial pancreatectomy alone or in combination with 
local injections of alloxan into the artery supplying 
the remaining pancreas (Mansour et al., 1990b; 
Reiser et al., 1987). In cats rendered diabetic by 
such methods, Mansour et al. (1990b) documented a 
significant increase in retinal capillary basement 
membrane thickness following 3-10 months of 
diabetes. Hatchell et al. (1994a) reported 
hemorrhages, microaneurysms, non-perfusion and 
IRMA as early as 7.5 yr in diabetic ats followed for 
9 yr. Funduscopic examination was facilitated since 
cats do not develop diabetic ataracts. 
6.3. Diabetic Non-human Primates 
Non-human primates hould be good models for 
diabetic retinopathy because their retinas have a 
fovea and a pattern of vascularization and capillary 
structure almost indistinguishable from that of human 
retinas. However, developing diabetic retinal 
microangiopathies n monkeys on a consistent basis 
has been difficult. In spite of the many approaches 
which have been used to induce diabetes, retinal 
lesions have been observed only rarely, even after 10 
W. G. Robison et al. 
yr of diabetes, and the results are inconsistent (Frank, 
1994). There is no clear documentation f pericyte 
loss or basement membrane thickening. Jonasson et 
al. (1985) found only the mild non-proliferative stage 
of diabetic retinopathy in a large series of monkeys 
with up to 12 yr of streptozotocin-induced diabetes. 
Microaneurysms have been reported occasionally, 
but seldom with supporting micrographs (Bresnick 
et al., 1976; Danis and Wallow, 1986; Gibbs et al., 
1969). Several investigators have expressed their 
frustrations with the difficulty of inducing diabetic 
retinopathy in non-human primates. Nevertheless, 
recent preliminary results (Laver et al., 1994) suggest 
that a spontaneously diabetic monkey colony 
described and maintained by Hansen et al. (1991, 
1994) may provide a source of meaningful models 
for several diabetic retinal microangiopathies 
characteristic of the non-proliferative stages. A 
classical Type II non-insulin dependent diabetes 
mellitus develops in middle-aged rhesus monkeys of 
this colony. After diabetes durations of 1-8 yr, these 
monkeys had varied amounts of pericyte 
degeneration, statistically significant thickening of 
retinal capillary basement membranes, capillary 
dilation, acellularity, occlusion, endothelial cell 
proliferation and a few microaneurysms (Laver et 
al., 1994). Because of the potential importance of a 
reliable non-human primate model for diabetic 
retinopathy, such leads merit further investigation. 
6.4. Diabetic Dogs 
A spontaneously diabetic dog was the first 
experimental model of a near complete spectrum of 
angiopathies characteristic of diabetic retinopathy 
(Patz and Maumenee, 1962). Its discovery dispelled 
the concept which had been developing for some 
time that diabetic retinopathy might be a diabetic 
vascular complication unique to human diabetes. A
dog that had spontaneous diabetes for approximately 
3 yr demonstrated pericyte degeneration with ghost 
formation, microaneurysms, acellularity, endothelial 
cell proliferation and putative exudates, along with 
cataracts and kidney lesions. Apparently, some 
microaneurysms exhibited loss of pericytes and 
proliferation of endothelial cells, while others 
demonstrated hyalinization (Patz and Maumenee, 
1962). No IRMA or proliferative retinopathy 
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developed. Later, Patz et al. (1965) reported several 
early lesions of non-proliferative r tinopathy in seven 
out of 12 spontaneously diabetic dogs. Engerman 
and Bloodworth (1965) reported non-proliferative 
retinopathy in two out of five dogs with 
metasomatotropin-induced diabetes and in one out of 
five with alloxan-induced iabetes. They added 
intraretinal hemorrhage to the list of the lesions of 
non-proliferative r tinopathy which can be produced 
in diabetic dogs. Although not identified as such by 
them, their so-called 'oversize hypercellular 
capillary' could be classified as IRMA because of its 
size and large, irregular branches. Although retinas 
were examined histologically after 9, 15, 34, 37, 41, 
43, 53, 67 and 69 months of diabetes, only those 
from the three dogs with durations of more than 43 
months developed the retinal microangiopathies. 
Gepts and Toussaint (1967) reported typical non- 
proliferative diabetic retinal microangiopathies n 22 
out of 30 diabetic dogs. The microangiopathies 
included pericyte ghosts, focal loss of endothelial 
cells as well as pericytes, generalized acellularity of 
capillaries, irregularly-dilated (varicose) capillaries, 
and typical microaneurysms. Sibay and Hausler 
(1967) documented saccular microaneurysms and 
hypercellular dilated capillaries, which could be 
classified as IRMA, in a dog that was diabetic for 5 
yr, while only dilated capillaries were observed in a 
dog that was diabetic for 2 yr. Several additional 
studies (Bloodworth, 1967; Bloodworth and Molitor, 
1965; Engerman et al., 1977; Toussaint, 1968) have 
confirmed the validity of the diabetic dog as a model 
of diabetic cataracts and essentially all the non- 
proliferative stages of diabetic retinopathy. However, 
in all these studies, microangiopathies r quired 48-60 
months to develop, and proliferative stages have 
never been reported. Identification of the earliest 
retinal lesions in diabetic dogs has not been 
determined. Although some evidence suggests 
capillary basement membrane thickening and pericyte 
loss occur early (Stitt et al., 1994), just when they 
happen and which takes place first is not established. 
6.5. Galactose-fed Dogs and Rats 
A more complete diabetic-like spectrum of retinal 
microangiopathies can be induced in non-diabetic 
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dogs and rats fed a galactose diet than has been 
reported in any other animal model (Engerman and 
Kern, 1984; Frank et al., 1983; Kador, 1990; Kador 
et al., 1988, 1990, 1994; Robison et al., 1983, 1986, 
1988, 1989a, 1990c, 1991a; Robison and Laver, 
1993; Takahashi et al., 1992). This discovery has 
not only provided agreat asset o research on diabetic 
retinopathy, but it offers insight into the underlying 
mechanism of diabetic retinopathy. Galactose-fed 
animals have normal plasma glucose levels, but they 
share an important abnormality with diabetic humans. 
They accumulate high tissue levels of polyol 
(Sections 12.4 and 13.2), indicative of increased 
aldose reductase activity, which has been implicated 
in many diabetic complications (Dvornik, 1987; 
Frank, 1994; Fukushi et al., 1980; Gonzfilez et al., 
1984; Kinoshita and Nishimura, 1988; Nishimura et 
a/., 1988a). So, while galactose-fed animals would 
not be expected to manifest he full complement of 
physiological changes characteristic of diabetes, they 
would be expected to develop aldose reductase- 
related tissue complications. In fact, the 
complications should generally occur sooner and/or 
be more severe since aldose reductase has a higher 
affinity for galactose than for glucose (Hayman and 
Kinoshita, 1965), resulting in more polyol synthesis 
under hypergalactosemic than hyperglycemic 
conditions. Also, unlike sorbitol, galactitol is not 
metabolized by the cell, so polyol accumulates more 
rapidly (Fig. 2) and reaches much higher levels in 
tissues of galactose-fed animals than diabetic animals 
(Dvornik, 1987; Dvornik et al., 1988, 1994; Stewart 
et al., 1968; Section 12.4). As expected, polyol- 
related tissue complications uch as cataracts and 
keratopathy do, indeed, occur sooner in galactose-fed 
animals (Dvornik, 1987; Kinoshita and Nishimura, 
1988; Robison et aL, 1990a; Robison and Laver, 
1993). Sugar cataracts develop in galactose-fed rats 
in 2-3 weeks compared to 2-3 months in diabetic 
rats (Fukushi et al., 1980; Hu et al., 1983). The rate 
of cataract development is directly related to the per 
cent of dietary galactose, severity of galactosemia 
and lens polyol accumulation i  galactose-fed rats 
(Dvornik, 1987; Simard-Duquesne and Dvornik, 
1973; Simard-Duquesne et al., 1985). 
Based on its potential for accelerating the 
development of aldose reductase-related diabetic 
complications, galaetose was fed to animals with the 
hope that diabetes-related retinal microangiopathies 
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would also occur sooner. The positive results 
obtained suggested that diabetic retinopathy, like 
cataracts, is also a tissue complication related to 
aldose reductase activity. Not only dogs fed 30% 
galactose (Engerman and Kern, 1984; Kador, 1990; 
Kador et al., 1988, 1990, 1994), but also rats fed 
either 30 or 50% galactose (Frank et al., 1983; Kern 
and Engerman, 1995; Robison et al., 1983, 1986, 
1989a, 1990c, 1991a; Robison and Laver, 1993; 
Laver and Robison, 1993) responded to elevated 
tissue polyol evels by developing diabetic-like r tinal 
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7. SIMILAR/TIES BETWEEN GALACTOSE 
MODELS AND HUMAN DIABETIC 
RETINOPATHY 
Although the retinas of dogs and rats have no 
fovea and their major vessels form unique arrays, 
their capillaries are similar in diameter, meshwork 
patterns and ultrastructure to human retinal capillaries 
(Figs 3-5). As in human diabetes, the capillaries of 
the posterior, central retina were the first structures 
to show signs of retinopathy in galactose-fed animals 
(K_ador et al., 1990; Robison et al., 1991a; Robison 
and Laver, 1993; Takahashi et al., 1992). The types 
of microangiopathies and the sequence patterns, 
which developed through the high-risk proliferative 
stage in the dog and the mild proliferative stage in 
the rat, were extraordinarily similar to those of 
diabetic retinopathy in humans. 
As in diabetic patients, the earliest 
histopathological retinal lesions (Figs 4 and 5) are a 
diffuse thickening of capillary basement membranes 
and degeneration f the intramural capillary pericytes 
of the central retina (Robison et al., 1983, 1986, 
1988, 1989a, 1990c; Robison and Nagata, 1988; 
Robison and Laver, 1993; Kador, 1990; Kador et al., 
1988, 1990; Takahashi et al., 1992). The earliest 
significant increase in retinal capillary basement 
membrane thickness has not been clearly documented 
in humans or these animal models. Previously, it was 
reported to occur as early as 7 months in rats fed 
50% galactose (Robison et al., 1983, 1986), but is 
now known to take place as early as 6 months (Fig. 
5; Robison et al., 1993). As in humans (Carlson, 
1989; Carlson and Bjork, 1990; Toussaint and Dustin, 
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Fig. 2. Rapid tissue polyol accumulation i lens epithelium. 
A, Sorbitol in rats rendered iabetic by streptozotocin i jec- 
tion [-- -  non-diabetic (n = 3); - - * - -  diabetic (n = 6); 
- -O - -  diabetic plus AL-1576 (n = 6); ~ non-di- 
abetic plus AL-1576 (n = 1)]. B, Galactitol in rats fed a 30% 
galactose diet [ ...... non-galactosemic (n -- 3); - -<>- -  galac- 
tosemic (n = 6); - -0 - -  galactosemic plus AL-1576 (n ffi 
6); and m __ __ non-galactosemic plus AL-1576 (n = 1)]. 
The aldose reductase inhibitor, AL-1576 (4 mg/kg /day ,  
was administered every 24 hr by garage. 
changes in capillary basement membranes in 
galactose-fed animals. The thickened basement 
membranes have a greater tendency to become 
multilaminar and vacuolated as well as acquire 
various electron-opaque inclusions such as fibrous 
collagen and degenerated pedcyte remnants (Frank 
et al., 1983; Robison et al., 1983, 1986, 1988). 
When the pericytes degenerate, they leave 
empty-appearing pockets in the ensheathing basement 
membranes, often called pericyte 'ghosts' (Figs 4 
and 5). Pericyte ghosts first appear in galactose-fed 
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Fig. 3. Similarity of microvessels in human and rat retinas. Retinal vessels from a rat (A) fed 50% galaetose for 6 months 
beginning at weaning; and from an 86-yr-old diabetic person (B). All arteries (A), veins (V) and capillaries (C) appeared 
normal at this magnification. Note the typical avascular zone of the macular (M) region in the human. PAS/hematoxylin stain. 
Both calibration bars represent 500 p.m. Reproduced from Robison and Laver (1993) by permission and courtesy of 
Smith-Gordon and Co. Ltd. 
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Fig. 4. Intramural pericyte loss in human retinal capillaries. A, Light micrograph of capillaries from the perimacular region of 
Fig. 3B, showing intramural perieyte ghosts (pg) and nuclei of normal endothelial cells (e) and pericytes (p). B, Electron 
micrograph of a capillary from a similar region of the companion eye, Showing a normal red blood cell (rbc), lumen (L) and 
endothelial cell lining (e), but abnormally thickened basement membrane (bin) and degenerated cytoplasmic remnants in all the 
intramural pericyte compartments (pg). The calibration bars represent 10 and 1.0 ~m, respectively. 
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dogs after 19 months (Kador et al., 1988) and in 
galactose-fed rats after 6 months or less (Fig. 5). In 
humans, the first appearance of pericyte ghosts has 
not been determined with certainty (Section 5.1), but 
it occurs before clinical signs of retinopathy (Figs 3B 
609 
and 4). The possible mechanisms of pericyte loss and 
its relation to subsequent clinical lesions will be 
discussed in Section 12.4. 
In galactose-fed animal models, as in humans, 
there are two different ways that capillaries respond 
Fig. 5. Intramural pericyte loss in rat retinal capillaries. Retinal capillaries from rats fed 50% galactose for 6 months beginning 
at weaning showing, by light microscopy with PAS/hematoxylin stain, A, an intramural pericyte ghost (pg), without anucleus, 
as well as endothelial cells (e) and pericytes (p) with normal nuclei; and, by electron microscopy, B, a capillary with a normal 
lumen (L) and endothelial cell lining (e), but abnormally thickened basement membrane (bm) and degenerated cytoplasmic 
remnants representing pericyte ghost (pg) cytoplasm inall the intramural pericyte compartments. The calibration bars represent 
10 and 1.0 ixm, respectively. 
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Fig. 6. Diabetes-related microangiopathies n rats and humans. Retinal vessels from a rat fed 50% galactose for 24 months 
beginning at weaning, A, and from a 62-yr-old diabetic person who had utilized insulin for 15 yr, B. In both cases, many 
microaneurysms (ma) and acellular capillaries (ac) are present and some of the smaller arteries (A) and veins (V) have become 
tortuous. However, the most striking changes, when compared to the normal appearing structures observed in Fig. 3, are 
capillaries that have become irregularly dilated to extraordinary diameters to form tortuous, hypercellular channels and dilated 
meshworks (din and arrowheads). PAS/hematoxylin stain. Both calibration bars represent 500 ~m. 
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Fig. 7. Diabetes-related microangiopathies in rats and humans. Retinal vessels from a rat fed 50% galactose for 24 months 
beginning at weaning, A, and from a 58-yr-oid diabetic individual who had utilized insulin for more than 13 yr, B. In both 
cases, intramural pericyte ghosts (pg), lightly-stained acellular capillaries (ac) and darkly-stained, apparently occluded 
capillaries (oc) are present. However, the most striking changes, when compared to the normal appearing structures seen in Fig. 
3, are capillaries which have become irregularly dilated (de) to extraordinary diameters to form cylindrical microaneurysms 
(cm), tortuous, hyperceUular channels and dilated meshworks (din) in association with both arteries (A) and veins (V) and 
accompanied byperivascular glial proliferations. PAS/hematoxylin stain. Both calibration bars represent 50 i~m. 
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Fig. 8. Types of microaneurysms in rat retinas. Retinal vessels from rats fed 50% galactose for 24 months, showing several 
types of microaneurysms (ma), including saccular, A, fusiform with hyalinization, B, cylindrical, C, and irregular, D. The 
microaneurysms are accompanied by dilated capillaries (dc), capillaries with pericyte ghosts (pg) and acellular capillaries (ac), 
many of which appear to be occluded (oc), as judged by their degree of PAS staining. The microaneurysms can occur near the 
middle of the capillary plexus or in close association with arteries or veins (V). PAS/hematoxylin stain. The calibration bar 
represents 30 ~m for all micrographs. 
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to pericyte loss. Some capillaries, in which pericytes 
have degenerated, exhibit a proliferation of 
endothelial cells and dilate to several times their 
original diameters, thus approaching the diameters of 
the major retinal vessels (Kador et al., 1990; Robison 
et aL, 1989a, 1991a, Robison and Laver, 1993). 
Focal dilations result in microaneurysms, whereas 
more extensive dilations create hypercellular 
channels, shunts and other IRMA, some of which 
form dilated meshwork patterns (Cogan and 
Kuwabara, 1963; Cogan et al., 1961). By contrast, 
other capillaries, which are often adjacent, respond 
in an essentially opposite way. Instead of dilating, 
these capillaries maintain a normal diameter and lose 
their endothelial cells as well as their pericytes. As in 
humans (Ashton, 1983; Kuwabara nd Cogan, 1965), 
such capillaries become acellular, non-functional nd 
eventually are filled with glial cell cytoplasm 
(Robison and Laver, 1993; Robison et al., 1990c). 
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The areas of acellularity occur mainly in the central 
retina and are often closely associated with 
hypercellular channels, microaneurysms and IRMA 
(Figs 6 and 7) - -  a pattern very characteristic of 
human diabetic retinopathy. 
Microaneurysm formation in the polyol-induced 
retinopathy of dogs and rats appears to be very 
similar to that in human diabetic retinopathy. 
Microaneurysms form by 27 months in galactose-fed 
dogs and as early as 16 months in galactose-fed rats. 
The types of microaneurysms include saccular, 
fusiform, cylindrical (tubular) and irregularly-shaped 
as well as many aggregations of the same (Fig. 8). 
Some are hyalinized, but most are patent. These 
exhibit the characteristic microaneurysm structure in 
transection, having an endothelial cell lining devoid 
of pericytes as in humans (Yanoff, 1969), and a 
lumen filled with erythrocytes (Fig. 9). Saccular 
microaneurysms are often observed in galactose-fed 
Fig. 9. Patent microaneurysm in a rat retina. Retinal micrograph from a rat fed 50% galactose for 28 months howing a 
transected microaneurysm ( a) in the inner nuclear layer (INL) with red blood cells (arrows) in the lumen and an endothelial 
cell lining (en) devoid of pericytes. The microaneurysm has a diameter far exceeding the normal diameter (arrowhead) of 
vessels in the inner nuclear layer, and is accompanied by a partially disrupted outer nuclear layer (ONL) with many surviving 
rod (m) and cone (cn) nuclei. The calibration bar represents 25p~m. Reproduced from Kinoshita et al. (1990). 
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rats (Fig. 8A), but occur less frequently in rats than 
in dogs or humans (Robison et al., 1989a; Robison 
and Laver, 1993). The cylindrical microneurysms are 
often associated with perivascular glial proliferation 
(Fig. 7). 
Capillary dilations that involve longer segments 
have been variously called tubular microaneurysms, 
hypercellular channels (Kohner and Henkind, 1970) 
or capillary ensheathing (Cogan et al., 1961) in 
descriptions of human diabetic retinopathy. Similar 
structures occur in both galactose-fed dogs and rats 
(Kador et al., 1990; Robison et al., 1989a, 1991a; 
Robison and Laver, 1993). When the hypercellular 
channels involve relatively extensive capillary 
segments and include several branches and 
anastomoses in the plexus network (Figs 6 and 7), 
they have been called dilated meshworks (Robison 
et al., 1989a). All these anomalies are the histological 
correlates of the clinically visible group of lesions 
called IRMA, which probably involve intraretinal 
neovascularization (de Venecia et al., 1976) and 
may act as shunts (preferential channels). In humans, 
they are characteristic of the severe non-proliferative 
stage of diabetic retinopathy and are highly predictive 
of proliferative retinopathy (Davis, 1991). In 
galactose-fed rats, IRMA are more prominent han 
microaneurysms in that they occur more frequently 
and involve more of the total capillary length. 
'Dot and blot' hemorrhages occur by 33 months 
in galactose-fed dogs and can be observed clinically. 
In galactose-fed rats, hemorrhages occur by 24 
months, but histological sections are required for 
their demonstration because the galactose-induced 
lens opacity is greater in rats. Likewise, hard exudates 
and cotton-wool spots occur in galactose-fed rats as 
well as dogs, but in rats they canbe observed only in 
sectioned retinas. As in humans, veins become dilated 
and tortuous in galactose-fed rats (Fig. 6; Robison et 
al., 1989a). 
Recently, extraretinal neovascularizations were 
documented in galactose-fed dogs after 72 months 
(Kador et al., 1994; Takahashi et al., 1992) and 
galactose-fed rats after 24-28 months (Laver and 
Robison, 1993), suggesting even greater similarity 
with humans and usefulness of these models of 
diabetic retinopathy. As in humans, the new vessels 
tend to develop first on or surrounding the optic disc. 
It is noteworthy that the regular occurrence of 
diabetic-like retinal microangiopathies through the 
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severe non-proliferative stage in galactose-fed rats 
has been confirmed by a completely independent 
laboratory (Section 13.5). 
As described (Sections 5 and 11), a specific 
spectrum of lesions is considered to be unique to 
human diabetic retinopathy. Although any one of the 
typical microangiopathies or some combination may 
occur in certain other retinal dysfunctions (Table 1) 
and some experimental models (Section 6), until 
now, the complete combination and pattern of lesions 
had not been demonstrated in any animal model. 
Presently, the entire spectrum of human-like diabetic 
retinal angiopathies can be produced on a regular 
basis in both galactose-fed dogs and rats, two very 
distinct animal models. 
Besides diabetic retinopathy, the retinopathy that 
most closely simulates the spectrum of lesions found 
in the galactose-fed dog and galactose-fed rat models 
is radiation retinopathy (Table 1; Sections 5 and 11). 
Radiation retinopathy occurs when patients receive a 
total dose of 6000 rads or more (Archer et aL, 1991; 
Chaudhuri et al., 1981; Hayreh, 1970; Maguire and 
Schachat, 1994). Like diabetic retinopathy, radiation 
retinopathy has a silent phase between the initial 
insult and the clinical expression of retinal 
microangiopathies, but this is significantly shorter. 
The latent period usually extends from 18 months to 
3 yr following radiation treatment. Like diabetic 
retinopathy, radiation retinopathy ismainly a vascular 
disease involving microaneurysms, intraretinal 
hemorrhages (mainly superficial), telangiectases, hard 
exudates, cotton-wool spots, macular edema, 
capillary non-perfusion, neovascularization, vitreal 
hemorrhages and retinal detachment. However, 
radiation retinopathy differs from diabetic retinopathy 
in that it has fewer microaneurysms, and there is a 
selective loss of capillary endothelial cells rather 
than pericytes. Although basement membrane 
thickening occurs, it only affects vessels larger than 
capillaries (Chaudhuri et al., 1981). The galactose- 
fed animals experienced no radiation, and their early 
selective loss of pericytes, capillary basement 
membrane thickening, and frequent microaneurysm 
formation, best match the microangiopathies 
observed in human diabetic retinopathy. 
Both the galactose-fed dog and the galactose-fed 
rat have distinct advantages over genetic or 
chemically-induced models of human diabetic 
retinopathy. The changes induced by galactose 
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feeding are more advanced and more like human 
diabetic lesions than those which develop in long- 
term diabetic animals. Not only do galactose-fed 
animals demonstrate l sions earlier, but they are 
otherwise more healthy and have normal ife-spans. 
Proliferative retinopathy has not been reported in 
diabetic dogs or rats. Diabetic rats usually do not live 
long enough to demonstrate more than capillary 
basement membrane thickening and pericyte loss 
(Robison et al., 1991b). By contrast, galactose-fed 
animals can develop retinopathy through the 
proliferative stages (Kador et al., 1994; Laver and 
Robison, 1993; Robison and Laver, 1993). 
Galactose-fed animals can be taken off the diet and 
returned to a normal physiological state within a few 
days. Thus, the effectiveness of intervening with 
therapeutic agents can be compared with complete 
removal of the physiological insult. This approach is 
not completely matched in any other animal model. 
The dog and rat models provide unique 
contributions for particular studies. The galactose-fed 
dog permits clinical monitoring of the progression of 
diabetic retinopathy b  ophthalmoscopic examination 
whereas the rat does not. Although cataracts are 
induced by galactose feeding in both models, some 
visualization of the fundus is still possible in the dog 
model since incomplete lens opacity and lens 
resorption are common in the dog, but not in the rat. 
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Alternatively, the rat develops retinopathy sooner, 
and is more practical and economical to maintain as 
well as handle. The fact that clinical evaluation is
unfeasible in the rat is partially compensated by the 
potential for greater availability of necropsy material, 
owing to the larger numbers of rats, which can be 
utilized within given limits of space and funds. 
Galactose-fed animal models and diabetic humans 
have two important features in common: (1) their 
abnormal accumulations of tissue polyol and (2) 
their extraordinarily similar patterns of retinal 
microangiopathies. This commonality plus the 
majority of other evidences suggest that he reduction 
of excess intracellular hexoses to their corresponding 
polyols by aldose reductase is the triggering event of 
diabetic retinopathy. 
8. POTENTIAL THERAPEUTICS: 
PREVENTION STUDIES 
Evidence that aldose reductase is, indeed, involved 
in the retinopathy of these newly available animal 
models of diabetes and that drug therapy is feasible 
emerged from studies involving treatment of 
galactose-fed animals with aldose reductase inhibitors 
(Kador, 1990; Kador et al., 1988, 1990; Robison et 
al., 1989a,b, 1990c; Robison and Laver, 1993; 
Takahashi et aL, 1992). 
Table 2. Effect of an Aldose Reductase Inhibitor (M79175) on Incidence* of Dog Retinal Angiopathies, 
Cataracts and HGB A IC Levels 
Lesion Months Control Galaetose diet//drug dose 
untreated 0.5 mg/kg 5 mg/kg 10 mg/kg 16 mg/kg 
Pericyte ghosts 36 0 /4  4 /4  
38 0 /4  4 /4  
Microaneurysms 36 0 /4  4 /4  
38 0 /4  4 /4  
Mean number per eye 36 15 
Mean number per eye 38 22 14 2 
Cataract severityt 
(6-36 month means) 0 2.5 2.1 0.7 
(5-38 month means) 0 2.2 
Hemorrhage 36 0 /4  1/4 3 /4  0 /2  
38 0//4 2//4 
38 2.20 -1- 0.27 2.83 4- 0.37 HGB A1C levels:~ 
4 /4  4 /4  
4 /4  1/2 
2 /4  1/4 
1/4 1/4 
1 2 
0.3, 2 /7  clear 0.2, 2 /6  clear 
0/4 0/4 
2.56 + 0.07 2.58 5:0.40 
* Incidence xpressed as the proportion of dogs showing the lesion. 
tCataract severity classified by slit-lamp exam on a scale of 0-4, with 4 being the most advanced cataract. 
:~Summary of HGB AIC levels determined by HPLC at 3-month intervals for the 4 dogs utilized in each group 
expressed as means + standard eviations. Modified from Table 2, Kador et al. (1994) with permission from the authors 
and the publisher. 
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A set of positive studies on dogs utilized a 
homogeneous population of 9-month-old normal 
males from an inbred laboratory strain of beagles, 
which were age-matched. Eyes were enucleated at 
different times, ranging from 19 to 38 months, 
permitting observation of diabetic-like retinal 
microangiopathies from the earliest signs through the 
formation of microaneurysms in untreated galactose- 
fed dogs (Kador, 1990; Kador et al., 1988, 1990, 
1994; Takahashi et al., 1992). The treated ogs were 
given different doses and combinations of the aldose 
reductase inhibitors orbinil (Pfizer, Groton, Ct.) and 
M79175 (Eisai, Tokyo, Japan) administered by oral 
tablets both before and after a single daily 30% 
galactose meal. The sorbinil doses ranged from 59 to 
105 mg/kg/day, while the doses of M79175 ranged 
from 0.5 to 16 mg/kg/day. The body weights 
remained equivalent in treated and untreated groups 
throughout the experiment. The levels of 
galactosemia in all groups of galactose-fed dogs was 
also the same throughout, as determined by 
measurements of blood galactose and glycated 
hemoglobin levels at 3-4 month intervals (Table 2). 
Treatment with the higher doses of aldose 
reductase inhibitors (M79175 at 5-16 mg/kg/day) 
completely prevented 'dot and blot' hemorrhages 
through 38 months and significantly delayed all other 
diabetic-like retinal microangiopathies (Table 2). 
Pericyte ghosts normally occurred as early as 19 
months and microaneurysms as early as 27 months 
following commencement of galactose feeding in 
untreated ogs. Their appearance was delayed for 
several months in treated ogs, the degree of delay 
being directly correlated with drug dose and potency. 
A clear ameliorative ffect of inhibitor treatment was 
demonstrated by detailed analyses of several 
parameters (Takahashi et al., 1993). Although the 
lower doses delayed rather than prevented the retinal 
microangiopathies, the dose-related ameliorative 
responses uggest hat complete prevention rather 
than simply a delay of ocular complications in 
galactose-fed ogs is possible if enough aldose 
reductase inhibitor is maintained atthe cellular level. 
The similar glycated hemoglobin (HGB AIC) levels 
in untreated and inhibitor-treated ogs (Table 2) 
demonstrates that aldose reductase activity, and not 
glycation (Section 12.3), caused the diabetic-like 
retinopathy. The prevention of 'dot and blot' 
hemorrhages and dose-dependent delays of other 
retinal micr0angiopathies were directly correlated 
with amelioration of sugar cataracts in these same 
dogs (Kador, 1990; Kador et al., 1994; Sato et al., 
1991; Takahashi et al., 1992). 
Cataracts were completely prevented in one-third 
of the dogs treated with doses of 10-16 mg/kg/day 
(M79175), and their progression was significantly 
delayed by lower doses, in a dose-related manner. 
The complete prevention of cataracts in some of the 
inhibitor-treated dogs was important because the lens 
provides a 'built-in control' in diabetic and 
galactose-fed animal models: the maintenance of a 
clear lens gives the assurance that enough aldose 
reductase inhibitor eaches the lens on a regular basis 
to block polyol formation (Section 13.5). In the 
galactose-fed dogs, there was a direct correlation 
between the severity of cataracts and the degree of 
retinal damage. Those dogs which had clear lenses 
due to aldose reductase inhibitor treatment had 
minimal retinal microvascular change. Unless the 
conditions are met, in which inhibitor treatment is 
capable of ameliorating or completely preventing 
cataracts, there is no reason to expect complete 
prevention of other ocular complications (Robison 
and Laver, 1993, 1994). 
Negative findings with respect o the efficacy of 
aldose reductase inhibitor treatment of retinal damage 
in galactose-fed ogs have also been reported 
(Engerman and Kern, 1989, 1991, 1993; Kern, 1991; 
Kern and Engerman, 1991). These studies differed 
significantly in experimental design and 
interpretations from those used by Kador's group, as 
indicated in a recent evaluation (Robison, 1994). 
Instead of using aldose reductase inhibitors in such a 
way as to provide the highest levels of inhibition, 
only one, relatively low dose of aldose reductase 
inhibitor was employed. Instead of adjusting the 
inhibitor administration for ideal pharmacokinetics, 
the feeding of galactose was ad l ibitum and tablets 
with aldose reductase inhibitor were administered 
once in the morning and once in the evening. By 
contrast, in Kador's studies, galactose ingestion was 
limited to a single feeding and aldose reductase 
inhibitors were administered in three equal doses: 1 
hr before feeding, 1 hr after feeding and 8 hr after 
feeding. Probably sufficient levels of the aldose 
reductase inhibitor were not attained in the target 
tissues in the Engerman and Kern studies. 
Some of the problems, which make a meaningful 
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Fig. 10. Prevention of diabetes-related r tinal microangiopathies. Whole mounts of retinal vessels from rats fed a diet with 50% 
galactose for 24 months and treated, A, or untreated, B, with an aldose reductase inhibitor, sorbinil (65 mg/kg/day) for the 
duration of the experiment. Note that the normal structure of the capillary meshwork (m) was maintained along with a normal 
(ca. 1:1.6) ratio of pericyte (p) to endothelial (e) cell nuclei in the sorbinii-treated retina, whereas various microangiopathies 
including dilated capillaries (dc), seemingly occluded capillaries (oc), microaneurysms (ma), dilated meshworks (dm) and 
various complex microvascular bnormalities, which would be recorded clinically as intraretinal microvascular bnormalities 
(IRMA) developed in the untreated galactose-fed rat. X 300. The calibration bars represent 50 ~m. Reproduced from Robison 
and Laver (1993) by permission and courtesy of Smith-Gordon and Co. Ltd. 
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interpretation of the negative studies difficult 
(Robison, 1994), can be summarized as follows: (1) 
utilization of a single inhibitor dose; (2) lack of 
histological information on retinas until 42 and 60 
months following disease onset, when it is too late to 
see the delays in microangiopathies documented to
occur" between 20 and 38 months (Akagi and Kador, 
1990; Kador, 1990; Kador et al., 1988, 1990, 1994); 
(3) failure to prevent retinal capillary basement 
thickening (Engerman and Kern, 1991), which is a 
well-established ffect of adequate doses of aldose 
reductase inhibitors (Frank, 1994); (4) interpretation 
of polyol measurements on the whole retina given 
that the most important concentrations probably occur 
in the capillary pericytes, which would be grossly 
under-represented in whole retinas; (5) determination 
of retinal polyol levels only at termination of the 
experiment, when the fewest pericytes would be 
present; (6) lack of clear documentation of retinal 
microangiopathies by either micrographs or by 
quantitative morphometric analyses; and (7) failure 
to completely prevent cataracts in either the diabetic 
or galactose-fed ogs by the drug dose and/or 
administration used. Probably, the experimental 
design precluded finding a positive effect of 
inhibiting aldose reductase activity. 
Findings from inhibitor-treated, galactose-fed rats 
were very conclusive. Inhibitor treatment not only 
prevented cataracts, but also prevented capillary 
basement membrane thickening and the entire 
spectrum of diabetic-like microangiopathies through 
the mild proliferative stage (Fig. 10). In three studies 
totalling 115 rats (23 of which were galactosemic for 
> 24 months), galactose-fed rats had high blood 
levels of galactose (ca. 200 mg/dl) and polyol (ca. 
35 mg/dl) at 6, 18 and 24 months, but were relatively 
healthy and had normal life-spans. The retinas of 
untreated rats which were galactosemic for 24 months 
or more exhibited the full range of diabetic-like 
retinal microangiopathies through the mild 
proliferative stage (Section 7). All the lesions were 
essentially prevented with AL-3152, sorbinil, or 
tolrestat, three structurally distinct aldose reductase 
inhibitors. The inhibitors were evenly mixed with 
fresh diet at 0.1, 0.05 and 0.05% w/w, respectively 
(Laver and Robison, 1993; Robison and Laver, 1993; 
Robison et al., 1983, 1986, 1988, 1989a,b, 1990c, 
1991a). Aldose reductase inhibitor-treated 
galactosemic rats had lowered blood polyol levels 
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( < 3.0 mg/dl), but did not differ significantly from 
untreated galactosemic rats in blood glucose, 
galactose, or glycohemoglobin levels (Section 13.2). 
The treated rats also remained free of cataracts 
throughout a period of 28 months, indicating that the 
continual oral administration of an aldose reductase 
inhibitor was sufficient to prevent tissue damage 
(Section 13.5). 
These clear findings on the efficacy of aldose 
reductase inhibitors in preventing retinopathy in 
galactose-fed rats provide strong support for the 
positive effects of aldose reductase inhibitors in 
galactose-fed dogs and diabetic rats (Kojima et al., 
1985). Together, these independent s udies on the rat 
and dog models suggest that diabetic retinopathy in 
humans may be ameliorated by treatment with a 
sufficiently potent aldose reductase inhibitor, if 
treatment begins at the time of disease onset. 
9. POTENTIAL THERAPEUTICS: 
INTERVENTION STUDIES 
Since few clinical trials can be purely prevention 
studies, interventions in animal models are of 
inestimable value for determining how late therapy 
can be implemented and still have an effect. Now 
that diabetic-like retinopathy can be induced within a 
relatively short time in the new, galactose-fed animal 
models, intervention studies that were unfeasible 
previously can be undertaken. 
Thus, a combined prevention and intervention 
study was performed using a relatively new aldose 
reductase inhibitor (AL-3152) on galactose-fed rats 
(Robison et al., 1993) to test the possibilities of: (1) 
preventing diabetic-like retinopathy by constant 
inhibitor treatment from initiation of 50%-galactose 
feeding, and (2) delaying or halting diabetic-like 
retinopathy in spite of postponing intervention by 
addition of inhibitor or removal of galactose until 6 
months after galactosemia was induced. From rats 
killed at 6, 18 and 24 months, whole mounts of the 
retinal vasculature and transected whole retinas were 
used for morphometric analyses with a computerized 
image analysis ystem designed for 1024 × 1024 × 8 
bit resolution. The amount of capillary basement 
membrane thickening, pericyte loss, capillary 
dilation, microaneurysms, acellularity and total length 
of capillary were quantitated for each rat. Then the 
rats were scored from 0 to 10 based on the numbers 
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of lesions in all categories, with the Grade 0 
indicating no retinopathy and Grade 10 the maximum 
observed. 
At 6 months, when intervention was begun, the 
untreated galactose-fed rats exhibited a 30%, 
statistically significant (p < 0.01) increase in 
capillary basement membrane thickness, pericyte 
degeneration a d Grade 1 retinopathy overall. By 18 
months, the same group had Grade 7 retinopathy 
whereas the rats receiving intervention with either 
AL-3152-enriched or galactose-free diet exhibited 
only Grade 2 retinopathy, and the rats fed control 
diet or galactose plus AL-3152 throughout the 18 
months demonstrated no retinopathy. At 24 months, 
the untreated galactose-fed rats exhibited Grade 10 
retinopathy, while those receiving intervention by 
galactose removal had a Grade 8.5, and those 
receiving intervention with AL-3152 had a Grade 9. 
At 6, 18, and 24 months, all the rats that received 
galactose for 6 months or more had cataracts, except 
those that were treated from the beginning with 
AL-3152. All the galactose-fed rats had high levels 
of glycated (galactosylated) hemoglobin, whereas 
only the untreated galactose-fed rats had high plasma 
galactitol levels and developed diabetic-like 
retinopathy. In rats receiving intervention by removal 
of galactose, the retinopathy had progressed even 
though glycated hemoglobin and plasma polyol evels 
had been normalized. Because only rats which had 
high polyol levels for at least 6 months also exhibited 
retinopathy, it would appear that this diabetic-like 
complication is probably initiated by polyol 
accumulation and not by excessive tissue glycation, 
although increased glycation occurs with galactose 
feeding. The levels of glycohemoglobin did not 
correlate with either cataracts or retinopathy. In 
conclusion, cataracts and diabetic-like retinopathy 
are both prevented in galactose-fed rats if treatment 
with AL-3152 is started simultaneously with the 
galactose insult. But, intervention after 6 months by 
removal of galactose or addition of AL-3152 provides 
only a delay albeit a significant one. 
The findings in galactose-fed rats are consistent 
with intervention studies in diabetic animals 
(Engerman and Kern, 1987; McCaleb et al., 1991), 
which also indicate that reversal does not occur and 
halting of damage is limited. The effect of 
intervention therapy was studied in diabetic dogs 
receiving poor glycemic ontrol for 2.5 yr followed 
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by good glycemic control for another 2.5 yr 
(Engerman and Kern, 1987). No microaneurysms 
developed in the 2.5 yr of poor glycemic control. 
However, in spite of intervention with good glycemic 
control for the next 2.5 yr, many microaneurysms 
formed and the overall vessel damage was greater 
than that found in diabetic dogs receiving good 
glycemic ontrol for 5 yr. Intervention i humans by 
laser photocoagulation (Alello, 1994; ETDRS, 
1991d,f) or pituitary ablation (Speakman et al., 1966) 
decreases hemorrhages and proliferative changes, but 
does not reverse all the lesions of diabetic 
retinopathy. Pancreas transplantation i humans must 
be relatively early in order to demonstrate a clear 
effect (Petersen et al., 1990). 
The cumulative vidence indicates that probably 
only a delay or halting of ongoing degenerations is 
all that can be effected once diabetes-related retinal 
vessel damage has progressed significantly. Perhaps 
there is a damage threshold beyond which reversal is 
impossible, as in sugar cataracts (Hu et al., 1983; 
Simard-Duquesne and Dvornik, 1973). Once an 
intramural pericyte has degenerated, it would be 
replaced very slowly if at all (Engerman et al., 
1967). So, while prevention therapy could completely 
prevent loss of pericytes, intervention therapy would 
only be expected to prevent any further loss of 
pericytes. Assuming that pericyte loss initiates 
subsequent vessel esions (Section 12.4), halting of 
pericyte loss by intervention would not halt 
subsequent lesions in those capillaries that had 
already lost several pericytes. The disease progression 
would be expected to continue until the effects of 
lost pericytes were exhausted. Evidence of beneficial 
effects of intervention therapy may be masked for a 
long time, until such existing tissue damage 
completely reveals its consequences. 
I0. CLINICAL TRIALS 
Insofar as plasma glucose can be maintained at 
normal levels, the complications of diabetes hould 
be preventable. Insulin is a miracle drug for an 
increasing number of people whose lives depend on 
artificially maintaining blood glucose levels in a near 
normal range. Insulin treatment, when designed to 
provide the tightest possible blood glucose control 
by multiple injections or continuous ubcutaneous 
insulin infusion pumps (DCCT, 1993; Reichard et 
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al., 1993; Santiago, 1992), has significantly delayed 
the progression of diabetic omplications, including 
diabetic retinopathy. This is what would be expected 
if hyperglycemia and/or the metabolic products of 
glucose are the initiating factors. However, tight 
glucose control methods are not able to bring the 
blood glucose below supernormal evels nor 
completely normalize glycosylated hemoglobin levels 
in all patients (DCCT, 1993; Reichard et al., 1993; 
Santiago, 1992; Zinman, 1989). Tight control brings 
problems of its own, such as higher isks of increased 
body weight, hypoglycemic shock and ketoacidosis 
(DCCT, 1993; Reichard et al., 1993; Santiago, 1992). 
The methods used to obtain tight glucose control 
would be difficult to implement in the general 
population of diabetic patients without significant 
risks. A new approach to preventing diabetic 
complications i  needed. 
Aldose reductase inhibitors used in addition to 
conventional insulin treatment have the potential of 
blocking the toxic effects of the supernormal levels 
of glucose, which the best insulin therapy is unable 
to avert. A 3-yr, multi-center clinical trial to test the 
aldose reductase inhibitor sorbinil as a 
complementary treatment of diabetic retinopathy 
demonstrated no clear beneficial effect, although it 
did indicate "...a slightly slower progression rate in 
the microaneurysm count among patients assigned to 
take sorbinil..." (Sorbinil Retinopathy Trial Research 
Group, 1990, p. 1234). Why were negative results 
found in the clinic when the animal data (Sections 8 
and 9) predicts potential beneficial effects? There are 
at least three possible explanations: (1) less than 
adequate drug dosing; (2) intervention too late 
with respect to disease progression; and/or (3) study 
too short to distinguish between the full expression 
of existing damage and beneficial effects of therapy. 
Drug levels probably played a very important 
role, as suggested by animal studies, which 
demonstrated a direct correlation between drug dose 
and the ameliorative ffects of aldose reductase 
inhibitors (Section 8). Intervention time and length 
of the study were undoubtedly very important also. 
Prevention studies can 'be designed to be 
straightforward in animals (Section 8). However, 
most clinical trials are intervention studies by nature 
and, as such, are plagued with many unknown 
variables related to the degree of tissue damage 
present at the time of intervention (Section 9). 
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Intervention with good glycemic ontrol in diabetic 
dogs led to the conclusion that "...retinopathy may 
be preventable but tends to resist arrest even in its 
incipient stages, before more than the first few 
aneurysms have appeared..." (Engerman and Kern, 
1987, p. 808). The acceptance riteria for the sorbinil 
trial included patients with as many as five 
clinically-visible (patent) microaneurysms and an 
unknown number of occluded microaneurysms and 
microscopic lesions such as pericyte loss, capillary 
basement membrane thickening and endothelial cell 
proliferation. Concerns regarding the amount of such 
existing damage at the time of first clinical detection 
of diabetic retinopathy were expressed years ago, 
when retinal flat mounts first permitted 
histopathological correlations: "...it has not 
previously been realized how surprisingly numerous 
micro-aneurysms are and the picture is a depressing 
one for one wonders how it can ever be possible to 
reverse such a gross and widespread process by the 
administration of drugs or the control of diet. At best 
we can only hope to prevent he development of 
such lesions or, once the condition is established, to 
attempt to control the hemorrhages..." (Ashton, 1950, 
p. 41). The sorbinil study was relatively short 
compared to the time required for diabetic retinopathy 
to develop. It is possible that a beneficial effect of 
sorbinil would have been distinguishable from the 
progression of existing damage had the study lasted 
longer than 3 or 4 yr. This appears to be the most 
plausible explanation why relatively short-term 
studies on the efficacy of tight blood glucose control 
(Kroc Collaborative Study Group, 1984) failed to 
demonstrate an ameliorating effect on diabetic 
retinopathy. Recent long-term trials (DCCT, 1993; 
Reichard et al., 1993; Santiago, 1992) demonstrated 
a clear benefit, which would have been missed if the 
studies had been terminated earlier. 
Findings from recently completed clinical trials 
and studies on animal models of diabetic retinopathy 
suggest hat future clinical trials would benefit by 
including some of the following: (1) earliest possible 
intervention; (2) more potent and/or higher doses 
of inhibitors; (3) inhibitors with better 
pharmacokinetics; (4) longer trials; and (5) means 
for earlier diagnosis. A current multicenter t ial to 
test the efficacy of tolrestat (Macleod et al., 1992) 
has incorporated many of these features. 
Tolrestat has pharmacokinetics (Dvornik et al., 
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1988, 1994) consistent with a once-a-day dosing in 
humans (plasma half-life of 12 hr), has been 
demonstrated to be efficacious in preventing 
diabetic-like retinopathy in rats (Robison et al., 
1989a, 1990c), is well-tolerated in humans (Sima et 
al., 1993; Santiago et al., 1993), and has been 
demonstrated to interrupt the diabetes-induced 
progressive loss of nerve function in a double-blind, 
placebo-controlled clinical trial involving 372 
patients with a long history of diabetic neuropathy 
(Santiago et al., 1993). This effect on nerve function 
was associated with reduction in structural signs of 
axonal degeneration, decreased incidence of myelin 
abnormalities and increased evidence of fiber 
regeneration. Currently tolrestat is being evaluated in 
long-term clinical studies in patients with diabetic 
nephropathy and retinopathy. 
11. SUBORDINATE HYPOTHESES: 
COMPONENTS OF THE 
PATHOPHYSIOLOGICAL SPECTRUM 
Although there is a spectrum of retinal 
microangiopathies unique to diabetic retinopathy 
(Section 5), various facets of the spectrum are 
exhibited in other disorders and may develop from 
secondary factors held in common. A single 
hypothesis probably defines the initial lesion (Section 
12.4), but several subordinate hypotheses may be 
needed to explain the individual secondary changes 
in the triggered chain of events leading to the final 
complexity of vessel damage in diabetic retinopathy. 
Probably, the more advanced the lesion, the greater 
the possibility of it having a multi-factorial origin. 
As expressed by Bloodworth (1964, p. 81), "Diabetic 
retinopathy is a combination of degenerative, 
proliferative, and exudative lesions of vascular and 
parenchymal tissues." Indeed, many hypotheses have 
been proposed and variously modified over the years 
to explain the component retinal angiopathies 
individually or as groups. It has been proposed that 
microaneurysm formation may involve more than 
one mechanism acting in concert, with pericyte 
dysfunction being the primary aberration 
(Fryczkowski et al., 1991). Biochemical studies on 
the mechanisms of diabetic retinopathy have been 
classified into two categories (Frank, 1994) as 
follows: (1) those determining the earliest lesions 
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(triggering events) and (2) those that might contribute 
to retinal-vitreal neovascularization. A discussion of 
all the hypotheses proposed to date is beyond the 
scope of this review, so only a select number will be 
covered with emphasis on the ones that might explain 
some of the major component angiopathies (Sections 
11.1-11.5) or define the primary event (Section 12). 
Neovascularization will not be discussed since it is a 
late event and is the subject of many recent reviews 
(Bobik and Campbell, 1993; Casey et al., 1994; 
Davis, 1994; D'Amore, 1994; Forrester et al., 1993; 
Glaser, 1994a; Grant et al., 1993; Klagsbrun and 
D'Amore, 1991; Sunderk~itter t al., 1994). The sum 
of the evidence in this section suggests that, while 
various vessel occlusive factors and perfusion 
pressure contribute to the spectrum of lesions 
characteristic of diabetic retinopathy, they probably 
do not represent the initiating event or provide an 
explanation for all the changes that develop, Capillary 
lesions are involved in the greatest number of 
angiopathies, uggesting that they are closer to a 
primary event han arteriolar and venular aberrations 
(Fig. 1). 
11.1. Rheological Anomalies Related to 
Occlusions 
Many characteristics of retinal blood flow become 
altered in diabetes and have been considered to be 
candidates for underlying factors in the development 
of diabetic retinopathy (Feke et al., 1994; Frank, 
1994). Hatchell and Sinclair (1994) proposed that 
abnormal leukocyte rheology could be a prime cause 
of diabetic retinal microangiopathies. They suggested 
that leukocyte activation alone could initiate enough 
endothelial cell damage to induce capillary occlusion, 
whereas platelet aggregation, increased whole blood 
viscosity or decreased erythrocyte deformability 
would not produce sufficient change. They 
hypothesized that leukocyte activation may gel the 
cytoplasm and result in decreased cell deformability 
and increased leukocyte adherence to endothelial 
cells. 
Naturally occurring human disorders provide 
insight regarding certain diabetes-related 
angiopathies. One example, which relates to a 
potential role of increased blood viscosity and flow 
resistance in angiopathies, is the sickling cell 
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condition. This disease involves an inherited change 
of erythrocyte shape and flow characteristics (Cohen 
and van Houten, 1994; Goldberg, 1976; Lutty et al., 
1994; Stefansson et al., 1983). The sickle cell 
retinopathy that develops (Garner, 1994) includes 
hemorrhages, vessel tortuosity, arteriolar occlusions, 
arteriolar-venular anastomoses, areas of non- 
perfusion, cotton-wool spots and proliferative 
retinopathy. Compared to diabetic retinopathy, the 
hemorrhages tend to be much larger, the arteriolar 
occlusions are mainly equatorial and peripheral, the 
cotton-wool spots are extremely rare, and the 
neovascularization is mainly in the peripheral retina. 
Notably absent are microaneurysms and hard 
exudates. 
11.2. Capillary Occlusion and Ischemia 
Capillary occlusion has been suspected as a 
primary cause of diabetic retinal lesions. Radiation 
retinopathy induced in monkeys (Irvine and Wood, 
1987) could be considered a test for the potential 
role of capillary occlusion and ischemia. As in 
diabetic retinopathy, the first changes occur in the 
small capillaries of the deep plexus. As in human 
radiation retinopathy (Archer et al., 1991; Chaudhuri 
et al., 1981; Hayreh, 1970; Maguire and Schachat, 
1994) and diabetic retinopathy, there is a delay 
('silent' period) before any effects of the insult 
can be detected. After approximately 12 months, 
there is a focal loss of endothelial cells and 
then pericytes" from the capillary walls. These are 
followed by capillary occlusions and subsequent 
occlusions of larger vessels with accompanying 
non-perfusion and cotton-wool spots. Finally, 
microaneurysms, increased permeability, intraretinal 
neovascularization a d rubeosis iridis develop. The 
lesions are similar to those of diabetic retinopathy 
except that there are fewer microaneurysms, no 
intravitreal neovascularization, a d the first lesion is 
the selective loss of endothelial cells rather than 
pericytes. 
Retinal ischemia was induced experimentally in
cats by raising the intra-ocular pressure, by 
photocoagulation of individual arteries or by 
embolization of capillaries with sterile fat emulsions 
(Reinecke et al., 1962). The retinal capillaries 
responded similarly to all three methods. Ischemia 
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lasting less than 90 min resulted in endothelial cell 
proliferation in the capillaries,-while ischemia for 
longer periods caused an initial increase in endothelial 
cell number, then a loss of endothelial cells, and 
finally pericyte degeneration, leaving acellular 
capillaries. Laser-induced occlusion of retinal 
arterioles in rats resulted in increased numbers of 
neutrophils in retinal capillaries (Hatchell et al., 
1994b). This suggests involvement of neutrophils in 
capilary plugging and a possible contribution to the 
non-perfusion observed following acute retinal 
ischemia. 
11.3. Arterial and Arteriolar Occlusions 
Michaelson (1980) suggested that arteriosclerosis 
is a prominent feature of diabetic retinopathy. Ashton 
(1953, 1963) presented histological evidence for 
narrowing of arterioles in eyes with diabetic 
retinopathy and suggested that ischemia is the basic 
problem of diabetic retinopathy. Focal occlusions of 
small arterioles are common in diabetic retinopathy 
and occur mainly in the posterior pole where other 
diabetic angiopathies develop. The microinfarctions 
result in the clinical appearance of cotton-wool spots 
(Destro and Gragoudas, 1994) which may occur very 
early in diabetic retinopathy (Kohner et al., 1969). 
The retinal effects of arterial occlusion are 
demonstrated by naturally occurring disorders uch 
as ocular ischemic syndrome and retinal obstructive 
disease. The characteristics of these disorders are 
dilated veins, hemorrhages (often in macula), 
microaneurysms in the midperiphery, cotton-wool 
spots, vessel eakage, and neovascularization  the 
disc and elsewhere (Brown, 1994a,b). Notably absent 
are numerous microaneurysms in the posterior pole, 
tortuous vessels and IRMA, when compared to 
diabetic retinopathy. Cogan (1974) reported that a 
diabetic patient developed typical non-proliferative 
retinopathy in one eye, but had no funduscopicaUy 
visible diabetic microangiopathies n the contralateral 
eye, which previously had an occlusion of the central 
retinal artery. 
Experimental occlusion of retinal arteries in cats 
induced the formation of many arterio-arteriolar nd 
veno-venous shunts as well as capillary acellularity 
(Henkind, 1966). However, no arterio-venous shunts 
or microaneurysms developed, both of which are 
very characteristic of diabetic retinopathy. 
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11.4. Venous and Venular Occlusions 
Many, but not all, aspects of diabetic retinopathy 
are mimicked by venous occlusion. Experimental 
venous occlusion was produced in a non-diabetic 
monkey eye by a laser burn accurately applied to 
avoid retinal artery damage (Hamilton et al., 1974). 
The resulting closure of the retinal vein induced 
essentially all the lesions that occur in human retinal 
venous occlusion (Cogan, 1974; Weinberg and 
Seddon, 1994), but did not exhibit all the angiopathies 
of diabetic retinopathy. There were intraretinal 
hemorrhages (but mainly small and flame-shaped), 
capillary dilations, preferential (enlarged and 
tortuous) channels within the capillary bed, tortuous 
venules, areas of capillary non-perfusion, secondary 
arteriolar and venule occlusions and eventual 
revascularizations (Hamilton et al., 1974). Notably 
missing were microaneurysms, pre-retinal 
neovascularization a d cotton-wool spots. Other 
experimental models of venous occlusion (Wallow et 
al., 1991) have developed capillary and venous 
collaterals within the retina, similar to those 
characteristic of diabetes. However, no 
microaneurysms developed and the intramural 
pericytes remained unchanged or increased in their 
coverage of the capillary surface (Wallow et al., 
1991). 
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having many exudates not confined to the posterior 
pole, having fewer microaneurysms mainly 
associated with the arterial side of the retinal 
circulation, having mainly flame-shaped rather than 
punctate hemorrhages, and having basement 
membrane thickening of arterioles, but not capillaries. 
In addition, there is no selective loss of pericytes. 
Collateral channels induced by experimental 
occlusion of retinal arteries developed no 
microaneurysms in spite of carrying blood under 
pressure probably in excess of that normally present 
in the capillary plexus (Henkind, 1966). 
12. MAJOR HYPOTHESES: UNDERLYING 
MECHANISMS OF DIABETIC 
RETINOPATHY 
The major hypotheses proposed to explain the 
underlying mechanism and possible triggering lesion 
of diabetic retinopathy are the following, in 
approximate order of greatest supporting evidence: 
(1) increased aldase refluctase activity (Frank, 
1991a, 1994; King and Banskota, 1994); (2) non- 
enzymatic glycation (Frank, 1991a, 1994; King and 
Banskota, 1994) (3) altered redox potential (King 
and Banskota, 1994); and (4) the diacylglycerol- 
protein kinase C pathway (King and Banskota, 
1994). 
11.5. Vessel Dilation and Vascular Perfusion 
Pressure 
It has been proposed that retinal vessel dilation 
and wall stretching caused by increased retinal blood 
flow, increased perfusion pressure and/or vessel 
occlusion could cause many diabetic retinal 
microangiopathies involving endothelial cell 
proliferation and neovascularization (Stefansson et 
al., 1983). It was suggested that added luminal 
pressure could cause the endothelial cells of venules 
and capillaries to stretch, leak at junctions, and 
proliferate, producing microaneurysms, capillary 
dilation, and neovascularization. Hypertension 
retinopathy can. serve as a test of hypotheses 
involving increased tension (Anand and Tasman, 
1994; Brown and Benson, 1984; Garner, 1994). It 
results in retinal hemorrhages, cotton-wool spots, 
marked papilledema, hard exudates and capillary 
non-perfusion. It differs from diabetic retinopathy in
12.1. Key Involvement of Hyperglycemia 
Certainly hyperglycemia (or excess in any blood 
hexose) must play the principal role in the 
development of diabetic retinopathy and must be 
central to any hypothesis proposed. The importance 
of hyperglycemia h s been recognized by several 
investigators (Ashton, 1959; Davis, 1988; Frank, 
1994; Garner, 1994). Strong supporting evidence 
includes the following: (1) relation of glucose control 
to retinopathy in diabetic dogs (Engerman and Kern, 
1987; Engerman et al., 1977); (2) a similar 
relationship in epidemiological studies (Klein et al., 
1988); (3) demonstration that diabetic retinopathy is 
directly related to blood glucose levels (DCCT, 
1993); (4) the fact that Type I and Type II diabetes 
are very different in many ways, including origin, 
development, carbohydrate metabolism, fat 
metabolism and insulin levels (Fong and Rand, 1994), 
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yet they share similar retinopathies and chronic 
hyperglycemia (Cogan, 1974); and (5) the fact that 
diabetic-like retinopathy can be induced in normal 
animals by a galactose diet (Sections 6.5 and 7). The 
galactose-fed animal permits isolation of the effects 
of high blood hexose from all other complicating 
factors of the systemic disease. This permits a clear 
distinction between systemic diabetes and the 
complication (diabetic retinopathy). In galactose-fed 
animals, the plasma levels of insulin and glucose 
remain normal, yet diabetic-like retinopathy develops 
(Sections 6.5 and 7). The retinopathy must result 
solely from high hexose (galactose) or the products 
of its metabolism. 
indicates that inhibition of sorbitol dehydrogenase in 
diabetic animals accelerates cataract formation, a 
finding expected with polyol involvement, but not 
expected if altered NADH/NAD ratio were the 
primary event. In order for altered redox potential or 
increased flux through the diacylglycerol-protein 
kinase C pathway to be considered primary causative 
factors, independent of aldose reductase activity, the 
source of increased NADH/NAD ratio would have 
to be demonstrated to occur prior to aldose reductase 
action and the glucose-induced increase in redox 
potential should not be prevented by aldose reductase 
inhibitors. 
12.2. Altered Redox Potential and 
Diacylglycerol-Protein Kinase C Pathway 
Both of these hypotheses are secondary to the 
increased activity of aldose reductase that is induced 
by hyperglycemia. The additional f ux through the 
polyol pathway that occurs in diabetes increases the 
intracellular ratio of NADH/NAD (King and 
Banskota, 1994; Williamson et al., 1993), creating a
condition called pseudohypoxia (Williamson et al., 
1993) because the NADH/NAD ratio is also altered 
when oxygen deficits prevent oxidation of NADH to 
NAD +. Not only would the redox potential be 
increased, but there could be an increased flux 
through the diacylglycerol-protein ki ase C pathway, 
explaining the increased protein kinase C activity 
observed in diabetic tissues (King and Banskota, 
1994). However, consideration of these hypotheses 
as primary would fail to explain evidence from 
galactose-fed animals. The proposed alteration of the 
redox potential requires not only increased reduction 
of excess hexose to polyol by aldose reductase, but 
also the oxidation of the polyol (sorbitol to fructose 
in diabetes) by sorbitol dehydrogenase. Since, unlike 
sorbitol, galactitol is not metabolized by the cell, no 
NADH is produced by the polyol pathway in 
galactose-fed animals, yet they develop a retinopathy 
indistinguishable from diabetic retinopathy (Section 
7). Glycolysis, another potential source of an 
increased ratio of NADH/NAD, has not been 
demonstrated to occur in galactose-fed animal 
models, although preliminary data has been 
mentioned (King and Banskota, 1994). Recent 
evidence (Geisen et al., 1994; Lee et aL, 1995) 
12.3. Glycation (Non-enzymatic Giycosylation) 
Glycation is an important direct cumulative ffect 
of hyperglycemia. It involves the non-enzymatic 
covalent bonding between free aldehyde groups on 
any of several sugars and amino groups of proteins, 
usually lysines (glucose - -  glycosylation; galactose 
- -  galactosylation; fructose - -  fructosylation; and so 
on). The initial products of glycation are unstable 
Schiff bases that become stabilized by undergoing a 
reduction. Then they develop susceptibility to 
oxidation, undergoing repeated glycation-oxidation 
cycles and becoming highly crosslinked in 
irreversible reactions involving other compounds 
(Amadori rearrangements). Both intermediate and 
advanced end-products of glycosylation (AGE), such 
as ketoamides (early products of the Maillard, or 
browning reaction) resist turnover and accumulate in
multiply-crosslinked moieties. The accumulation of 
glycoxidation products precedes continually, as a 
facet of the normal aging process, and is significantly 
accelerated in diabetic subjects (Baynes, 1991; Bunn 
et al., 1978; Sternberg et al., 1985). In non-diabetic 
individuals, the glycoxidation products accumulate 
mainly in extracellular matrix components such as 
tissue collagens. However, under diabetic onditions, 
significant accumulations also occur intracellularly, 
in cells that do not require insulin for glucose uptake 
(Chiou et al., 1980; Nagaraj and Monnier, 1992; 
Nagaraj et al., 1991). Since glycation is a chronic, 
non-enzymatic process directly related to glucose 
levels, which causes marked accumulations of 
irreversible reaction products (advanced glycation 
end-products), it has been attractive to propose its 
involvement in diabetic complications (Brownlee, 
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1990; Brownlee et al., 1988; Perry et al., 1987). 
However, hard evidence for a cause-effect 
relationship between glycated end-products and 
diabetic retinopathy is not yet available. 
The main report which claims to have 
demonstrated prevention of retinal microangiopathies 
by inhibiting the formation of advanced glycation 
end-products (Hammes et al., 1991) is not 
accompanied by adequate supporting data. Although 
37.5% (three out of eight) of the untreated iabetic 
rats and none of the aminoguanidine-treated rats
were reported to have microaneurysms, the 
micrograph presented (their Fig. 2c) as raw data does 
not demonstrate a microaneurysm, but a twisted 
capillary, or perhaps a capillary loop (Garner, 1970) 
combined with an adjacent twist. Therefore, the 
numerical data presented are of questionable value 
and do not provide the support needed to identify 
glycation as an initiating cause of diabetic 
retinopathy. The increase in glycation end-products 
reported in the capillary basement membranes of 
diabetic rats is expected based on human studies 
(Sternberg et al., 1985), but there is no unequivocal 
evidence that the increased glycation contributes to 
the thickening of basement membranes in humans or 
animals. A thickened basement membrane would be 
expected to become more heavily glycated solely on 
the basis of the additional material available for 
glycation. The only agents known to unequivocally 
prevent diabetes-related basement membrane 
thickening are inhibitors of aldose reductase (Das et 
al., 1990; Frank et al., 1983; Robison and Nagata, 
1988; Robison et al., 1983, 1986, 1988), which have 
no significant effects on plasma glucose levels in 
diabetic rats (Kemper and Dvornik, 1986; Yue et al., 
1984) or on blood hexose and glycohemoglobin levels 
in galactosemic rats (Robison et al., 1989a, 1993; 
Yue et al., 1984; Section 13.2). 
Aspirin has been reported to inhibit glycation and 
delay cataract formation in streptozotocin diabetic 
rats (Cherian and Abraham, 1993; Swamy and 
Abraham, 1989), but it is not efficacious in 
preventing diabetic cataracts or delaying the 
progression of retinopathy in diabetic patients, 
according to recent clinical trials (Seddon et al., 
1991; ETDRS, 1991b). Perhaps glycation should be 
considered to be a possible factor in rendering some 
of the diabetes-induced alterations in vascular 
structure irreversible. However, long-term studies on 
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animal models of diabetes are needed to determine 
the efficacy of various guanidines, including 
aminoguanidine, and/or other agents that inhibit 
formation of glycoxidation products (Fu et al., 1994) 
or block the recently proposed link with nitric oxide 
formation (Tilton et al., 1993). 
Meanwhile, the bulk of the evidence is consistent 
with a primary role for aldose reductase activity in 
ocular complications of diabetes (Section 12.4), but 
would not be expected if glycation were the initiating 
event: (1) although blood glucose levels can be very 
high (ca. 500 mg/dl) in the diabetic rat, the blood 
galactose levels remain relatively low (ca. 200 
mg/dl) in the galactose-fed rat (Robison et al., 
1989a), yet sugar-induced cataracts and retinopathy 
take much longer to develop in the diabetic than in 
the galactose-fed rat (Datiles et al., 1982; Robison 
et al., 1989a, 1990c, 1991b); (2) congenitally 
hyperglycemic mice with high glycation levels do 
not develop cataracts, even when fed galactose, 
apparently because their lenses exhibit only one-tenth 
of the aldose reductase activity found in rat lenses 
(Varma and Kinoshita, 1974); (3) the degu rodent, 
which is essentially normo-glycemic (150 mg/dl 
blood glucose) but has high lens aldose reductase 
activity, develops a cataract after ingesting normal 
laboratory rat chow and develops a cataract much 
sooner than any other rodent (within 10-12 days) if 
made diabetic (465 mg/dl blood glucose) by 
streptozotocin jection (Varma et al., 1977); (4) 
glycated hemoglobin levels remain unchanged in 
galactose-fed ogs and rats treated with aldose 
reductase inhibitors (Kador, 1990; Kador et al., 1990, 
1994; Engerman and Kern, 1991; Kern and 
Engerman, 1991, 1995; Robison and Laver, 1993; 
Robison et al., 1993; Section 13.2), yet cataract 
development and retinal vascular abnormalities are 
ameliorated (Kador et al., 1994; Robison and Laver, 
1993, 1994); (5) inhibition of aldose reductase 
prevents the galactose-induced cataracts in rats 
without decreasing the elevated glycosylation levels 
of the lens proteins (Chiou et al., 1980); (6) 
inhibition of aldose reductase prevents hexose- 
induced retinal capillary basement thickening (Frank 
et al., 1983; Robison et al., 1983, 1986) and 
advanced retinal microangiopathies in rats without 
altering the blood insulin, glucose, galactose 
(Robison et al., 1989a, 1990c; Robison and Laver, 
1993) or glycohemoglobin levels (Robison et al., 
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1993; Section 13.2); (7) although pentosidine starts 
accumulating soon after galactose feeding (Nagaraj 
et al., 1994), it remains to be demonstrated that 
advanced glycation end-products could accumulate 
fast enough to cause the rapid development of some 
complications of hyperglycemia such as the sugar 
cataracts (Section 12.4), which correlate closely with 
the incidence of diabetic retinopathy (Sections 8 and 
13.5); and (8) transgenic mice that express aldose 
reductase activity in the lens develop cataracts at 
rates directly correlated with the amounts of polyol 
that accumulate in diabetes and galactosemia (Lee et 
al., 1995), leaving little doubt that increased aldose 
reductase activity causes ugar cataracts. 
12.4. Aldose Reductase Activity 
Rapid accumulation of intracellular polyol, 
resulting from increased aldose reductase activity, is 
one of the first and most dramatic tissue responses to 
hyperglycemia in cells that do not require insulin for 
glucose uptake (Dvornik, 1987; Dvornik et al., 1988, 
1994; Kinoshita and Nishimura, 1988; Simfin et aL, 
1993). Polyol accumulation is accompanied by tissue 
damage. In sugar cataracts, the lens epithelium, which 
is the cell layer with the highest concentration of 
aldose reductase in the lens, incurs the earliest 
ultrastructural damage, correlated irectly with the 
rapid accumulation of polyol (Robison et al., 
1990a,b). 
In a series of experiments (Robison et al., 
1990a,b), Sprague-Dawley rats were made diabetic 
by streptozotocin i jection (50 mg/kg body weight 
in tail vein) or galactosemic by feeding a 30 or 50% 
galactose diet and were treated with one of two 
aldose reductase inhibitors (AL-1576: 4.0 
mg/kg/day or sorbinil: 65 mg/kg/day). Plasma 
sugar levels were monitored and rats were killed at 
several intervals during the first 6-120 hr after 
injection or diet administration, and at a few intervals 
up to 3 months later. Polyol levels were measured in
epithelium dissected free of contaminating fibers. 
Three to four individual epithelial ayers were pooled 
from different rats for each of the three to six 
samples analyzed in each group. The intracellular 
levels of sorbitol and galactitol were made using a 
modified liquid chromatography procedure, which 
permits detection in the picomole range (Dickerson 
and Lou, 1990). Whereas mature sugar cataracts ook 
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from 3 weeks to 3 months to develop in 50% 
galactosemic and diabetic rats, respectively, the 
epithelial cells demonstrated rapid changes in both 
polyol levels and ultrastructure. The lens epithelial 
cells of streptozotocin-induced diabetic rats exhibited 
a 24-fold increase in polyol (sorbitol) accumulation 
within 48 hr after streptozotocin i jection compared 
to controls (Fig. 2A). The lens epithelium of rats fed 
30% galactose after a 24-hr fast exhibited a 17-fold 
increase in polyol (galactitol) accumulation within 
only 36 hr of commencing the diet (Fig. 2B). Analysis 
by light and electron microscopy revealed that the 
first detectable histopathologies of the lens (as early 
as 36 hr in the 50% galactose-fed rats) occurred in 
the anterior, central ens epithelial cells. The salient 
lesions were cell edema, apparent dilution of 
cytoplasm, rounding of nuclei, aberrant intracellular 
vacuoles and loss of normal tortuosity of cell 
boundaries. No changes were detectable in the 
controls or in any of the rats treated with an aldose 
reductase inhibitor. The findings indicate a major 
role for aldose reductase in hyperglycemic damage 
to the lens epithelium. This layer is the principal site 
of the important regulator mechanisms that are lost 
early in sugar cataractogenesis. 
In retinal capillaries, the highest level of aldose 
reductase activity is in the intramural pericyte. Aldose 
reductase, its mRNA and its product (polyol) have 
been localized in pericytes, where one of the first 
histopathological lesions of diabetic retinopathy 
occurs. Immunohistochemical staining of aldose 
reductase in pericytes was demonstrated in trypsin- 
digested capillary whole mounts of dogs (Akagi et 
al., 1986) and humans (Akagl et al., 1983). 
Messenger RNA encoding for aldose reductase was 
identified in cultured human retinal pericytes by 
Northern blot hybridization (Nishimura et al., 
1988b). Aldose reductase activity was demonstrated 
in isolated dog retinal capillaries (Kern and 
Engerman, 1985), cultured monkey (Buzney et al., 
1977) and human (Hohman et al., 1989) retinal 
pericytes. The pericytes demonstrated rapid 
accumulation of polyols, vacuole formation and 
decreased proliferation when incubated in relatively 
high concentrations ( > 30 mM) of hexose sugars, but 
demonstrated control evels of polyols and no damage 
when an aldose reductase inhibitor was included. 
The recent in vitro demonstration of a 5.5-fold 
greater glucose transport activity in pericytes 
Aldose Reductase and Diabetic Retinopathy 
compared to endothelial cells and a selective down- 
regulation of glucose transport activity in pericytes 
(Mandarino et al., 1994) suggests a possible relation 
to the increased aldose reductase activity in pericytes 
and their selective loss in diabetes. Since aldose 
reductase is concentrated in a cell that is so 
strategically ocated in the capillary and is the first to 
degenerate, it is highly likely that polyol formation 
by aldose reductase activity is the primary triggering 
lesion of diabetic retinopathy. 
The mechanistic link between the toxic effects of 
aldose reductase activity in the pericyte and the 
histopathologies that develop subsequently is not 
completely understood. However, current evidence 
reveals close relationships between aldose reductase, 
early thickening of capillary basement membranes, 
early dysfunction and/or loss of intramural pericytes, 
endothelial cell proliferation and the formation of 
many proliferation-related vessel lesions. Basement 
membrane thickening is directly related to the polyol 
pathway and not to glycation. A diabetic-like 
basement membrane thickening was demonstrated in 
retinal capillaries of rats fed 50% galactose for 7 
months (Robison et al., 1983, 1988), 11 months 
(Robison et al., 1983), 22 months (Robison et al., 
1986) or 24 months (Robison et al., 1993) and in 
rats fed 30% galactose for 21 months (Frank et al., 
1983). The thickening was prevented with three 
structurally-distinct aldose reductase inhibitors in two 
independent laboratories. Although data on glycated 
hemoglobin was not included in those studies, it has 
been demonstrated subsequently (Robison et al., 
1993; Section 13.2) that glycation levels are not 
altered by treatment of galactose-fed rats with aldose 
reductase inhibitors, consistent with earlier findings 
on lens proteins (Chiou et al., 1980). Not only 
retinal capillary basement membrane thickening, but 
loss of pericyte-endothelial cell contacts, and the 
proliferation of retinal capillary endothelial cells were' 
prevented with aldose reductase inhibitors in 
galactose-fed rats (Robison and Laver, 1993; Robison 
et al., 1989b). 
There is an intriguing relationship between 
capillary basement membrane thickening and 
pericyte-endothelial cell interaction. A 2.4-fold 
increase in retinal capillary basement membrane 
thickening is accompanied by a 70% decrease in the 
number of cell-to-cell contact regions between 
pericytes and endothelial cells in rats fed 50% 
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galactose for 28 months (Robison et al., 1989b). 
Since each of the contact regions contains several 
different types of cell membrane junctional 
complexes, the loss of a cell contact fenestra could 
mean loss of various functions. Upon finding that 
pericyte degeneration, the primary lesion of human 
diabetic retinopathy, was "...accompanied by 
proliferation of vessels within the retina and into the 
vitreous...", Kuwabara and Cogan (1963, p. 498) 
proposed that pericytes normally control endothelial 
cell proliferation and thus prevent neovascularization. 
Crocker et al. (1970) observed that the endothelial 
cell proliferation, which results in new capillary 
growth during normal wound healing, ceased as the 
new vessels became nsheathed by pericytes and as 
cell contacts were formed. They hypothesized that a 
form of contact inhibition like that reported in cell 
culture might explain the decrease in cell proliferation 
with increasing numbers of cell contacts. Bovine 
retinal pericytes co-cultured with endothelial cells 
(Orlidge and D'Amore, 1987) inhibited their 
proliferation through the action of transforming 
growth factor [3 (TGF-I3). The loss of pericyte- 
endothelial cell contacts plus dysfunction of such a 
growth-factor-mediated mechanism ay be involved 
in the endothelial cell proliferation that is 
characteristic of diabetic retinopathy (Cogan et al., 
1961; Kohner and Henkind, 1970). It has been 
suggested that pericytes and their products might be 
involved in normal blood flow, capillary permeability 
and phagocytosis (Miller and Sims, 1986; Sims, 
1991; Sims et al., 1990), all of which would be lost 
with pericyte degeneration. Consideration of all the 
evidence suggests there is a link between pericyte 
aldose reductase activity and endothelial cell 
proliferation, a major contributor to subsequent 
intraretinal anomalies uch as microaneurysms and 
IRMA. 
13. SIGNIFICANCE OF THE 
GALACTOSE-FED RAT 
The galactose-fed rat provides the best evidence 
to date that aldose reductase activity is firmly linked 
to all the retinal lesions of diabetic retinopathy. The 
findings indicate that the reduction of excess hexose 
by aldose reductase is not only the triggering event, 
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but that it causes a cascade of cellular and tissue 
responses that ultimately result in all the 
microangiopathies of diabetic retinopathy through 
the mild proliferative stage. This model permits the 
dissociation of the effects of polyol accumulation 
from those of elevated blood glucose, elevated 
glycation levels, decreased insulin production and/or 
recognition, as well as other metabolic and genetic 
factors which might be involved in the development 
of diabetic complications. Only polyol-related 
complications and associated aspects }l~uld be 
manifest in a galactose-fed rat. Because of'its greater 
accumulation of polyol, the galactose-fed rat model 
also permits accelerated evelopment of polyol- 
related diabetic complications, a real advantage in 
studies of complications that take a long time to 
develop i.e. retinopathy. 
The fact that the galactose-fed rat closely mimics 
human diabetic retinopathy through the mild 
proliferative stage (Robison et al., 1983, 1986, 
1989a, 1990c; Robison and Laver, 1993; Laver and 
Robison, 1993) strongly suggests that the activity of 
aldose reductase is the primary causative factor. 
However, galactose feeding not only increases tissue 
polyol accumulation, but also glycation levels. 
Prevention of the retinopathy with aldose reductase 
inhibitors eliminates the possibility that glycation 
could be a major factor, since the inhibitors are 
specific and do not alter the plasma or tissue levels 
of hexose or glycation in the galactose-fed rat (Chiou 
et al., 1980; Kern and Engerman, 1995; Robison et 
al., 1989a, 1993). A complete prevention of cataracts 
and essential prevention of diabetic-like retinopathy 
has been documented in rats fed a 50% galactose 
diet plus one of three different aldose reductase 
inhibitors (AL-3152, sorbinil or tolrestat) for 24-28 
months (Robison et al., 1989a, 1990c, 1993; Robison 
and Laver, 1993; Sections 7-9). 
Although supporting data has been abundant, some 
concerns have been expressed regarding the 
galactose-fed rat as a model of the full spectrum of 
diabetic omplications: (1) do retinal pericyte ghosts 
occur in galactose-fed rats; (2) do the galactitol 
and/or  glycation levels correspond to vessel 
damage and degree of lesion prevention; (3) are the 
microaneurysms in rat retinas equivalent to those 
in humans; (4) why is retinopathy uncommon in 
galactosemic patients; and (5) can the prevention 
findings be repeated? 
13.1. Retinal Pericyte Ghosts 
The early occurrence of pericyte ghosts in any rat 
model of diabetes has been questioned (Frank, 1994; 
Frank and Das, 1992; Frank et al., 1983; Tilton et 
al., 1986). Nevertheless, abundant evidence 
supporting pericyte loss in rats has been presented by 
several independent laboratories. Pericyte ghosts, 
many of which have been documented by published 
high resolution light and electron micrographs, have 
been reported in retinal capillaries of various types 
of diabetic rats (Cohen and Rosenmann, 1990; Kern 
and Engerman, 1994; Kojima et al., 1975; Robison 
et al., 1991b; Sima et al., 1985) and in the 
galactose-fed rat model (Robison et al., 1989a, 
1990c; Robison and Laver, 1993). Kern and 
Engerman (1995) demonstrated pericyte ghosts 
within 15 months in retinal capillaries of rats fed 
either 30 or 50% galactose. Figure 5 demonstrates 
that pericyte ghosts not only occur in galactose-fed 
rats, but can be formed as early as 6 months after 
administration of a 50% galactose diet. 
13.2. Galactitol and/or  Glycation Levels 
The limited measuring of polyol levels in 
galactose-fed rats has raised concerns (Engerman 
and Kern, 1993). Blood was the only tissue measured 
in the original report of diabetic-like retinopathy 
through the severe non-proliferative stage in a 
galactose-fed rat. The average non-fasting blood 
polyol was 36 mg/dl in the untreated rats, 2.9 
mg/dl in the treated and less than 1.0 mg/dl in the 
controls (Robison et al., 1989a, p. 2290). Although 
total polyol rather than galactitol alone was reported, 
it is well established that essentially all the blood 
polyol is galactitol in galactose-fed rats (Dvomik, 
1987). The remainder is sorbitol at a concentration f
< 1.0 mg/dl. Measurements in tissues other than 
blood have been reported subsequently. The very 
rapid galactitol accumulation, which occurs in lens 
epithelium (Fig. 2B) is discussed in Section 12.4. 
A major concern in the galactose-fed rat is that 
the same levels of galactosemia be maintained in 
both untreated and treated groups of animals 
throughout the experiment. In the original 
experiments on the galactose-fed rat model (Robison 
et al., 1989a, 1990c), the blood galactose l vels were 
the same in both untreated and treated rats (216 and 
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235 mg/dl), and were undetectable in controls at the 
termination of the experiment (Robison et al., 
1989a). However, a much better assessment of 
galactosemia is accomplished by measuring the 
glycohemoglobin levels during the experiment. In a 
more recent experiment (Robison et al., 1993), 
glycohemoglobin levels measured at 6, 18 and 24 
months demonstrated no statistically significant 
differences between galactose-fed rats whether 
untreated or treated with the aldose reductase 
inhibitor AL-3152. A more rigorous monitoring of 
glycohemoglobin levels was performed by Kern and 
Engerman (1995) in their galactose-fed rats. Two 
important findings were demonstrated: (1) that an 
aldose reductase inhibitor (sorbinil) had no effect on 
glycohemoglobin levels, and (2) that there was no 
need to modify the feeding regimes (ad libitum in 
both) to maintain an equivalent level of 
glycohemoglobin in untreated and treated galactose- 
fed rats. These findings suggest hat all studies, 
which assure ad libitum feeding of a diet with a 
constant per cent of galactose will maintain 
comparable l vels of glycohemoglobin regardless of 
whether they receive an aldose reductase inhibitor or 
not. However, the repeated monitoring of 
glycohemoglobin levels serves as a double check on 
feeding behavior, when performed. 
13.3. Microaneurysms in Rat Retinas 
Concerns were raised by investigators who have 
been unable to demonstrate microaneurysms in rats 
fed a 30% galactose diet for 21 months (Frank, 
1991b, 1994; Frank and Das, 1992). Nevertheless, 
the majority of evidence indicates that 
microaneurysms do develop (Section 7), along with 
the other lesions characteristic ofdiabetic retinopathy 
through the mild proliferative stage (Figs 6-9). 
Confirmation that pericyte ghosts, acellular 
capillaries, hypercellular vessels (IRMA) and some 
microaneurysms in retinas of galactose-fed rats do, 
in fact, develop was recently reported by an 
independent laboratory. Using either a 50% or a 30% 
galactose diet (Kern and Engerman, 1995), multiple 
diabetic-like capillary lesions were demonstrated after 
15-26 months. Only the definition and interpretation 
of microaneurysms differed slightly. A narrow 
criterion for what was accepted as a true 
microaneurysm was employed: the capillary 
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aberration had to be saccular to be considered a
microaneurysm by Kern and Engerman (1995). The 
fact that other types of microaneurysms occur in 
humans, perhaps even more commonly than the 
saccular type, was not taken into account. Recently, 
the different ypes of microaneurysms in human 
diabetics were quantified from retinal digest 
preparations (Ghose et al., 1994). It was determined 
that 17% of the microaneurysms were saccular, 24% 
were irregularly shaped and 59% were spherical. 
Although more representative data are needed, it
appears that the saccular type of microaneurysm is 
not necessarily the predominant type in humans or 
rats. The distinction between microaneurysms and 
IRMA is somewhat ambiguous in rats, in which no 
standard definitions have yet been formulated. 
Therefore, the findings of Kern and Engerman (1995)~ 
are basically consistent with our earlier report 
(Robison et al., 1989a) that most of the 
microaneurysms of galactose-fed rats are fusiform, 
cylindrical (tubular) or irregular in shape rather than 
saccular. Even if many of the irregular 
microaneurysms were classified as IRMA, this would 
not invalidate the galactose-fed rat as a model of 
human diabetic retinopathy because IRMA are among 
the most predictive lesions of progression to 
proliferative retinopathy (Davis, 1991; ETDRS, 
19910. 
Many of the microaneurysms in rats have more 
capillary connections than the two which are thought 
to be characteristic, representing the afferent and 
efferent portions of a single capillary. However, 
humans with diabetic retinopathy also commonly 
exhibit microaneurysms with multiple capillary 
connections in digest preparations. They have been 
clearly documented by some investigators 
(Fryczkowski and Sato, 1986; Fryczkowski et al., 
1991) and appear to be present in the micrographs 
published by several others. Bloodworth (1962, Fig. 
21, Bloodworth, 1964, plate X) demonstrated a 
human microaneurysm with at least three clear 
connections and a possible forth. Wolter (1961, Figs 
12 and 13) also demonstrated microaneurysms with 
three and four connecting capillaries, in addition to 
several fibrous strands. The excellent scanning 
electron micrographs presented by Fryczkowski et 
al. (1991) leave no ambiguity. They demonstrate 
human diabetic retinal microaneurysms with three 
and four capillary connections. Therefore, contrary 
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to previous reports (Frank and Das, 1992), it appears 
that rats fed either a 30 or a 50% galactose diet are 
reliable models for the complete spectrum of diabetic 
retinopathies. 
13.4. Galactosemia in Humans 
Essentially all patients with congenital 
galactosemia have cataracts, as would be predicted 
from studies of galactose-fed rats. However, the 
clinical manifestation f retinopathy in these patients 
is uncommon, probably because galactosemia is
strictly controlled and/or the patients usually die 
before significant retinal changes would be expected. 
13.5. Can the Prevention Findings be Repeated? 
Kern and Engerman (1995) confirmed that 
galactose feeding induces increased tissue polyol, 
and a concomitant diabetic-like retinopathy through 
the severe non-proliferative stage, but they were 
unable to demonstrate a prevention with the aldose 
reductase inhibitor sorbinil. Nevertheless, several 
studies have demonstrated anessential prevention of 
all the galactose-induced retinal microanglopathies 
using any one of three different aldose reductase 
inhibitors (Robison and Laver, 1993, 1994). It is 
important o note that the rat studies, which have 
demonstrated a positive effect of aldose reductase 
inhibitors in the retina (Sections 8 and 9), have 
routinely found complete prevention of cataracts (no 
sign of opacity by slit lamp, gross exam, or histology) 
for at least 24 months in all galactose-fed rats treated 
with most of the aldose reductase inhibitors tested, 
including sorbinil. The only exception has been statil, 
which delays rather than prevents cataracts (Robison 
et al., 1992). By contrast, Kern and Engerman (1995) 
were unable to completely prevent cataracts. 
The failure to prevent cataracts uggests the key 
to interpreting the negative results in the retina. The 
lens, which retains all its cells throughout life, 
provides an accurate history of any past irreversible 
cellular insult, and thus serves as a good built-in 
control against experimental errors (Section 8). 
Sorbinil at the dose claimed is known to prevent 
cataracts for up to 24 months in rats fed 50% 
galactose (Dvornik, 1987; Robison and Laver, 1993, 
1994). Cataract formation in the sorbinil-treated rats 
(Kern and Engerman, 1995) indicates that the 
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expected target tissue levels of inhibitor were not 
obtained, probably due to a problem in sorbinil 
administration. Possibly uneven mixing or inadequate 
freshness of the sorbinil diet were factors. In any 
case, the inadequate dosing must have continued for 
at least 6 contiguous days during the experiment, 
since cataracts are reversible within 5 days by sorbinil 
treatment (Hu et al., 1983) or removal of the 
galactose diet (Simard-Duquesne and Dvornik, 1973). 
Regardless of how the aldose reductase inhibitor 
studies might be interpreted, it is clear that the 
galactose-fed rat as well as the galactose-fed dog, is 
a useful model of diabetic retinopathy. 
14. SUMMARY AND CONCLUSIONS 
Diabetic retinopathy is the major cause of 
blindness in adults (20-74 yr-old) in the 
industrialized countries. Whereas systemic diabetes 
mellitus results from lowered availability and/or 
cellular recognition of insulin, the complications of 
diabetes uch as diabetic retinopathy are caused by 
the chronic hyperglycemia itself. Although 
conventional insulin therapy lowers blood glucose 
levels enough to preserve life, it does not permit 
complete euglycemia nor prevent the long-term 
complications of chronic supernormal levels of blood 
glucose. Recent extensive clinical trials demonstrate 
that even intensive insulin treatment only delays 
diabetic complications, and it causes a 2-3-fold 
increase in severe hypoglycemia. This report presents 
experimental nimal evidence for the efficacy of a 
novel approach to preventing diabetic omplications, 
which would be used in addition to conventional 
insulin therapy, not to control blood glucose, but 
instead, to decrease the toxic effects of hyperglycemia 
on cells. 
The studies were made possible by the creation of 
a reliable and convenient animal model for diabetic 
retinopathy - -  the galaetose-fed rat. Probably the 
earliest toxic effect of elevated glucose levels in 
diabetic patients is increased aldose reductase 
activity, which leads to an intracellular accumulation 
of sorbitol, the polyol of glucose. By taking 
advantage of the fact that aldose reductase has a 
higher affinity for galactose than for glucose, much 
higher levels of polyol (galactitol) were attained in 
the cells of normal rats fed a 50% galactose diet than 
occurs in diabetic rats or humans (Fig. 2). The 
Aldose Reductase and Diabetic Retinopathy 
extraordinarily high polyol level accelerated sugar 
cataract formation and permitted the development of  
all stages of diabetic retinopathy through the mild 
proliferative stage within 24 months in galactose-fed 
rats (Figs 6 and 7) in contrast o diabetic rats, which 
never show more than the early stages. The 
galactose-fed rat model permits the dissociation of 
the effects of polyol accumulation from those of 
elevated blood glucose, insulin, and glycosylation 
levels, as well as other metabolic or genetic factors 
that might influence the development of diabetic 
complications. Only polyol-related or glycation- 
related complications should be manifest in untreated 
galactose-fed rats and only glycation-related 
complications hould develop in galactose-fed rats 
treated with an aldose reductase inhibitor. Since 
three inhibitors of aldose reductase with very different 
structures (Alcon 3152, sorbinil and tolrestat) 
prevented iabetic-like retinopathy (Fig. 10) without 
changing glycohemoglohin levels (Robison et al., 
1993), the activity of aldose reductase is probably 
the initiating event of diabetic retinopathy. Whether 
or not glycation could be involved as a secondary 
factor remains to be established. 
Substantial evidence indicates that abnormal 
accumulation of sorbitol resulting from activation of 
the enzyme aldose reductase of the polyol pathway is 
not only the best candidate for the initiating event of 
diabetic retinopathy, but also of many other ocular 
complications of diabetes. Prevention of sorbitol 
accumulation by oral administration of aldose 
reductase inhibitors has prevented sugar cataract 
formation, corneal edema, clouding and healing 
defects in both diabetic and galactose-fed rat models 
of diabetes. These findings identify a treatment that 
should be beneficial in humans, if used to compliment 
conventional insulin therapy. Aldose reductase 
inhibitors would protect against the toxic effects of  
the relatively low, yet supernormal levels of glucose 
that cannot be eliminated with insulin therapy. 
However, treatment should begin early, long before 
cl inical signs of  the compl icat ions;  drug 
pharmacokinetics should be considered thoroughly; 
and treatment should be continued on a long-term 
basis in order to prevent complications which take a 
long time to develop. 
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